{"gene":"RELB","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1992,"finding":"RelB contains a C-terminal transcriptional activation domain (last 180 amino acids) and does not bind NF-κB sites as a monomer, but forms heterodimers with p50-NF-κB that bind κB sites and transactivate κB-dependent promoters, unlike p50 homodimers which cannot transactivate.","method":"GAL4-RelB fusion transcriptional activation assays in yeast; EMSA; reporter gene (transactivation) assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (yeast transcriptional activation, EMSA, reporter assays) in founding characterization paper, replicated by subsequent work","pmids":["1732739"],"is_preprint":false},{"year":1994,"finding":"Human RelB (I-Rel) forms κB-binding heterodimeric complexes with p50 and p52 that potently transactivate κB-dependent constructs; it functions as a transactivator, not an inhibitor, consistent with murine RelB.","method":"Transfection reporter assays; EMSA with heterodimeric complexes","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (EMSA + reporter), single lab","pmids":["8183565"],"is_preprint":false},{"year":1995,"finding":"RelB is required for development of thymic medulla and dendritic cells; germline disruption of relB results in absence of RelB protein, dramatic reduction of constitutive κB-binding activity in thymus/spleen, loss of thymic dendritic cells, multiorgan inflammation, myeloid hyperplasia, and impaired cellular immunity.","method":"Targeted gene disruption (knockout mouse); EMSA; histology; contact sensitivity assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple defined cellular phenotypes, replicated by independent lab (PMID:7845467)","pmids":["7834753","7845467"],"is_preprint":false},{"year":1996,"finding":"Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent: RelB-KO × RAG-1-KO and RelB-KO × Nur77/N10-Tg mice are disease-free; B cells are not required for the phenotype.","method":"Genetic epistasis using double-mutant mice (RelB-KO × RAG-1-KO; RelB-KO × Nur77/N10-Tg; RelB-KO × p50-KO); histology","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean epistasis with multiple double-mutant combinations, clear cellular phenotype readout","pmids":["8892630"],"is_preprint":false},{"year":1997,"finding":"RelB is an important regulator of chemokine expression in fibroblasts: RelB-deficient fibroblasts show persistent, dramatically elevated expression of seven chemokines (RANTES, MIP-1α, MIP-1β, MIP-2, IP-10, JE/MCP-1, KC/CINC) after LPS stimulation, correlated with increased NF-κB binding; transfection of RelB cDNA into RelB-deficient fibroblasts reversed this overexpression.","method":"RelB-KO fibroblast LPS stimulation; EMSA; chemokine measurement; RelB cDNA rescue transfection; in vivo granulocyte recruitment assay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function (rescue) with specific molecular readouts, in vitro and in vivo","pmids":["9250151"],"is_preprint":false},{"year":2001,"finding":"RelB is associated in the cytosol with p100 (NF-κB2 precursor), not with IκBα, IκBβ, IκBε, or p105; p100 prevents RelB nuclear localization and transcriptional activity via amino acids 623–900 of p100, which contain a nuclear export signal; NF-κB-inducing kinase (NIK) overexpression, which promotes p100 processing via IKKα, induces RelB nuclear translocation.","method":"Co-immunoprecipitation; nuclear fractionation; reporter assays; structure–function analysis of p100 deletion mutants; NIK overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter assays, multiple orthogonal methods in single study","pmids":["11687592"],"is_preprint":false},{"year":2001,"finding":"RelA alone is sufficient to induce RelB gene transcription via a TATA-less promoter containing two NF-κB binding sites; the delayed nuclear translocation of RelB after TNF or LPS stimulation is secondary to increased RelB transcription, not to IκB-mediated cytosolic retention.","method":"Promoter cloning; reporter assays; EMSA with promoter κB sites; TNF/LPS stimulation time-course; nuclear fractionation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — promoter characterization with EMSA, reporter assays, and functional knockin/overexpression, multiple orthogonal methods","pmids":["11753650"],"is_preprint":false},{"year":2001,"finding":"RelB is required for germinal center formation, follicular dendritic cell networks, and marginal zone organization in spleen; reciprocal bone marrow transfers demonstrate that RelB expression in radiation-resistant stromal cells (not hematopoietic cells) is required for GCs, FDC networks, and MZ structures, whereas RelB in hematopoietic cells is required for MZ B cell generation. RelB-dependent homing chemokine expression (especially BLC) is strongly reduced in RelB-deficient spleen.","method":"RelB-KO mice; reciprocal bone marrow chimeras; immunofluorescence; RT-PCR for chemokines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal bone marrow transfers provide clean cell-extrinsic vs intrinsic dissection, multiple tissue/molecular readouts","pmids":["11489970"],"is_preprint":false},{"year":2001,"finding":"RelB serine 368 is critical for dimerization with other NF-κB family members but not for nuclear import; expression of functional RelB strongly reduces p52 generation and increases expression of p100 precursor by prolonging p100 half-life, suggesting RelB inhibits p100 processing.","method":"Site-directed mutagenesis (S368A/D); co-immunoprecipitation; Western blot for p100/p52; pulse-chase analysis of p100 stability in S107 plasmacytoma cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with co-IP and pulse-chase, single lab","pmids":["12874295"],"is_preprint":false},{"year":2001,"finding":"RelB undergoes signal-specific, proteasomal degradation upon T cell activation (TCR or TPA/ionomycin) but not TNFα stimulation; degradation proceeds through phosphorylation at Thr84 and Ser552, followed by an N-terminal cleavage, then complete proteasomal degradation; mutation of both phosphoacceptor sites stabilizes RelB.","method":"Phosphorylation site mutagenesis (T84A/S552A double mutant); Western blot; proteasome inhibitor treatment; TCR/TPA stimulation of T cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphosite mutagenesis with functional stabilization readout plus pharmacologic inhibition, single lab","pmids":["11781828"],"is_preprint":false},{"year":2003,"finding":"LTβR signaling induces RelB/p50 and RelA/p50 heterodimers, whereas TNF activates only RelA/p50; LTβR-induced RelB/p50 binding requires p100 processing mediated by IKKα but not IKKβ, NEMO/IKKγ, or RelA; TNF increases p100–RelB/p50 nuclear association, specifically inhibiting RelB DNA binding, providing two distinct p100-dependent mechanisms for signal-specific RelB regulation.","method":"Deficient MEF cells (IKKα-KO, IKKβ-KO, IKKγ-KO, RelA-KO); EMSA; Co-IP; LTβR and TNF stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic KO cell systems with EMSA and co-IP, clean dissection of signaling requirements","pmids":["12709443"],"is_preprint":false},{"year":2003,"finding":"RelB forms transcriptionally inactive heterodimers with RelA/p65; these RelA·RelB dimers are unable to bind κB DNA in vitro; overexpressed RelB significantly reduces TNFα-induced RelA activity; these complexes are not regulated by IκB proteins and are found in both cytoplasm and nucleus.","method":"Reporter gene assays; EMSA with in vitro translated proteins; co-immunoprecipitation; overexpression in MEFs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EMSA, reporter, co-IP), mechanistic characterization of a new dimer","pmids":["12657634"],"is_preprint":false},{"year":2003,"finding":"LTβR signaling activates p52-RelB heterodimers via NIK- and IKKα-dependent (but IKKβ- and IKKγ-independent) processing of p100; TNF activates RelA but specifically inhibits RelB by increasing p100–RelB/p50 complex formation; RelB/p52 is required for Peyer's patch development downstream of LTβR.","method":"Knockout mice (NF-κB2-KO, RelB-KO, LTβR-KO, NIK-mutant); EMSA; Western blot for p100/p52; genetic epistasis in vivo","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, EMSA, and in vivo epistasis","pmids":["12505990"],"is_preprint":false},{"year":2003,"finding":"RelB stabilizes itself through direct interaction with p100 (all domains engaged), p105, p52, and p50; p100–RelB complex formation requires unique N-terminal domain contacts and RelB's transcriptional activation domain interacting with p100's processing region; RelB protein levels are significantly reduced in the absence of p100 and further reduced when both p100 and p105 are absent.","method":"Co-immunoprecipitation; domain deletion/mutagenesis of p100 and RelB; Western blot in p100-KO and p100/p105-double-KO cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic domain mapping with reciprocal co-IP and genetic cell models, multiple orthogonal methods","pmids":["18321863"],"is_preprint":false},{"year":2003,"finding":"RelB is the NF-κB subunit required for dendritic cell-mediated NKT cell development via a NIK-dependent pathway; RelB must be expressed in irradiation-resistant, CD1d-negative host stromal cells (not hematopoietic cells) for NKT cell development; compound heterozygous RelB+/− × aly/+ mice have reduced NKT cell responses, demonstrating in vivo genetic interaction between NIK and RelB.","method":"RelB-KO and NIK-mutant (aly/aly) mice; bone marrow chimeras; compound heterozygous epistasis; flow cytometry; in vitro NIK kinase assay with RelB activation readout","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — bone marrow chimeras, compound heterozygous epistasis, and in vitro kinase signaling, multiple orthogonal approaches","pmids":["12810685"],"is_preprint":false},{"year":2003,"finding":"1α,25-dihydroxyvitamin D3 (and analogs) directly represses RelB transcription through VDR·RXRα binding to vitamin D response elements in the relB promoter; mutagenesis of these VDREs abolishes suppression; NF-κB response element mutagenesis does not affect vitamin D suppression, ruling out indirect NF-κB effects.","method":"Promoter VDRE identification; gel shift assays (VDR·RXRα binding); reporter assays with VDRE mutagenesis; VDR overexpression; DC-derived cell lines; in vivo VDR-KO mouse comparison","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutagenesis, gel shift, reporter assays, in vivo VDR-KO confirmation, multiple orthogonal methods","pmids":["14507914"],"is_preprint":false},{"year":2005,"finding":"Vitamin D receptor-mediated relB promoter suppression in dendritic cells involves direct VDR binding to the relB promoter and recruitment of HDAC3 (but not HDAC1 alone); HDAC3 association is enhanced by D3 ligand and reduced by LPS; HDAC3 overexpression causes relB suppression, and HDAC3 depletion attenuates D3-mediated suppression.","method":"Chromatin immunoprecipitation (ChIP); HDAC inhibitor experiments; HDAC3 overexpression/siRNA knockdown; promoter reporter assays; in vivo VDR-KO mice","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, loss-of-function, gain-of-function, and in vivo genetic validation, multiple orthogonal methods","pmids":["16239345"],"is_preprint":false},{"year":2006,"finding":"IKKα regulates G1-to-S phase progression in pancreatic cancer cells by controlling p52/RelB-dependent transcription of the skp2 gene, which in turn regulates Skp2-mediated degradation of p27Kip1; IKKα siRNA increases p27 protein by downregulating Skp2.","method":"IKKα-specific siRNA; Western blot for p27/Skp2; ChIP at skp2 promoter for RelB/p52; reporter assays; cell cycle analysis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, siRNA, and cell cycle readouts in single lab","pmids":["16902410"],"is_preprint":false},{"year":2006,"finding":"RelB transcriptionally upregulates manganese superoxide dismutase (MnSOD) gene in aggressive prostate cancer cells; selective inhibition of RelB (by dominant-negative p100 mutant or siRNA) decreases MnSOD levels and significantly increases radiation sensitivity of prostate cancer cells.","method":"Dominant-negative p100 mutant; siRNA knockdown of RelB; Western blot for MnSOD; clonogenic radiation survival assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent inhibition approaches with functional radiosensitivity readout, single lab","pmids":["16261162"],"is_preprint":false},{"year":2006,"finding":"RelB induction during LPS endotoxin tolerance represses proinflammatory gene expression (e.g., IL-1β, TNFα); tolerant cells form transcriptionally inactive NF-κB p65/RelB heterodimers; siRNA knockdown of RelB in tolerant THP-1 cells restores endotoxin induction of IL-1β.","method":"THP-1 endotoxin tolerance model; RelB siRNA; reporter assays; co-immunoprecipitation of p65/RelB complexes; EMSA","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA rescue experiment, co-IP, and EMSA, single lab","pmids":["16951372"],"is_preprint":false},{"year":2007,"finding":"RelB physically interacts with the aryl hydrocarbon receptor (AhR); the RelB/AhR complex binds a novel RelB/AhR responsive element in the IL-8 promoter (distinct from classical DRE or κB sites) as well as xenobiotic responsive elements; AhR ligand TCDD promotes time-dependent recruitment of AhR to the RelB/AhR element via protein kinase A; RelB markedly increases TCDD-induced XRE reporter activity.","method":"Co-immunoprecipitation (RelB–AhR); ChIP (time-dependent AhR recruitment to IL-8 promoter); reporter assays; PKA inhibitor/activator experiments; EMSA","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, ChIP, reporter assays, and pharmacologic modulation, multiple orthogonal methods","pmids":["17823304"],"is_preprint":false},{"year":2007,"finding":"Constitutive de novo RelB synthesis in ERα-negative invasive breast cancer cells is driven by p50-p65 NF-κB and c-Jun–Fra-2 AP-1 complexes binding to the RELB promoter in synergy; ERα signaling inhibits RelB synthesis by reducing NF-κB and Fra-2 levels; RelB induces Bcl-2 to promote the invasive phenotype.","method":"EMSA; ChIP; reporter assays with promoter mutagenesis; siRNA knockdown; invasion assays; IHC correlation in breast cancer tissues","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, promoter mutagenesis, siRNA loss-of-function, and invasion phenotype, multiple orthogonal methods","pmids":["17369819"],"is_preprint":false},{"year":2007,"finding":"AhR/RelB complexes bind NF-κB elements on BAFF, BLC, CCL1, and IRF3 promoters in an ARNT-independent manner to drive their expression; TCDD induces this binding and gene expression in a RelB- and AhR-dependent manner in U937 macrophages.","method":"EMSA; ChIP; siRNA knockdown of AhR and RelB; RT-PCR for target gene expression; TCDD treatment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with EMSA and siRNA, single lab, multiple target genes","pmids":["17900530"],"is_preprint":false},{"year":2008,"finding":"The NF-κB p52:RelB heterodimer crystal structure reveals Arg125 of RelB contacts an additional DNA base pair; p52:RelB Arg125A mutant shows defective DNA binding and transcriptional activity selectively at κB sites with contiguous central A:T base pairs; p52:RelB binds a broader spectrum of κB sites than p50:RelA due to its ability to accommodate structural variation at AT-rich sites.","method":"X-ray crystallography of p52:RelB:κB DNA complex; site-directed mutagenesis (Arg125A); EMSA; transcriptional reporter assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and functional reporter assays","pmids":["19098713"],"is_preprint":false},{"year":2008,"finding":"RelB has a bipartite arginine/lysine-rich NLS that mediates binding to importin α5 and α6 for nuclear import; nuclear import of p52/RelB heterodimers is mediated exclusively by the RelB NLS, not the p52 NLS.","method":"In vitro binding assays with importin α isoforms; nuclear translocation assays; NLS-mutant RelB constructs; viral infection and TNF stimulation models","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assays and NLS-mutant constructs, single lab","pmids":["18462924"],"is_preprint":false},{"year":2008,"finding":"Daxx represses RelB target genes (dapk1, dapk3, c-flip, birc3/ciap2) by recruiting DNA methyltransferase 1 (Dnmt1) to their promoters in a RelB-dependent manner, resulting in DNA hypermethylation; methylation of target promoters is decreased in daxx-KO cells and restored by re-introduction of Daxx.","method":"ChIP; bisulfite sequencing/methylation analysis; daxx-KO and relB-KO cells; Daxx/Dnmt1 co-immunoprecipitation; reporter assays; stable transfection rescue","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, genetic KO with rescue, co-IP, and methylation quantification, multiple orthogonal methods","pmids":["18413714"],"is_preprint":false},{"year":2008,"finding":"RelB is required for osteoclast differentiation downstream of NIK; deletion of p100 restores differentiation of NIK-deficient OC precursors; overexpression of RelB (but not p65) rescues NIK-deficient precursors; RelB-KO precursors fail to form OCs and this defect is rescued specifically by RelB re-expression; RelB-KO mice show diminished osteoclastogenic response to TNFα in vivo.","method":"NIK-KO and RelB-KO mice; p100-KO epistasis; retroviral overexpression of RelB vs p65; in vitro osteoclast differentiation assays; in vivo TNFα challenge; B16 melanoma bone tumor model","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, rescue experiments, and in vivo validation","pmids":["18322009"],"is_preprint":false},{"year":2009,"finding":"RelB NF-κB reciprocally inhibits estrogen receptor α (ERα) synthesis in breast cancer cells by inducing expression of the zinc finger repressor Blimp1 (PRDM1), which then represses ESR1 gene transcription; PRDM1 induction by RelB involves Bcl-2/Ras signaling.","method":"siRNA knockdown of RelB; reporter assays for ESR1/PRDM1 promoters; Western blot and RT-PCR in breast cancer cell lines; ChIP; migration assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA, ChIP, and reporter assays with functional migration readout, single lab","pmids":["19433448"],"is_preprint":false},{"year":2010,"finding":"Human requiem protein (REQ/DPF2) acts as an adaptor molecule linking the NF-κB p52 subunit to the Brm-type SWI/SNF chromatin remodeling complex; REQ and Brm form a larger complex with RelB/p52 upon lymphotoxin stimulation and are recruited to the BLC (CXCL13) promoter; REQ knockdown suppresses anchorage-independent growth of cell lines with constitutively activated noncanonical NF-κB.","method":"In vitro binding assays; co-immunoprecipitation; ChIP at BLC promoter; siRNA knockdown of REQ and Brm; reporter assays; soft-agar anchorage-independent growth assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and ChIP with functional knockdown, single lab","pmids":["20460684"],"is_preprint":false},{"year":2011,"finding":"The paracaspase MALT1 cleaves RelB after Arg-85; RelB cleavage induces its proteasomal degradation and specifically enables DNA binding by RelA- or c-Rel-containing canonical NF-κB complexes; overexpression of uncleaved RelB inhibits canonical NF-κB target gene expression and impairs survival of DLBCL cell lines with constitutive MALT1 activity.","method":"In vitro MALT1 cleavage assay; mass spectrometry identification of cleavage site; proteasome inhibitor rescue; RelB overexpression in DLBCL lines; siRNA; reporter assays; EMSA","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro cleavage assay identifying specific site (Arg-85), MS confirmation, multiple cell-based validations","pmids":["21873235"],"is_preprint":false},{"year":2012,"finding":"During dendritic cell activation, RelB functions primarily as a RelB–p50 dimer regulated by canonical IκBs (IκBα and IκBɛ), not as the expected RelB–p52 effector of the noncanonical pathway; IκB control of RelB minimizes spontaneous DC maturation but enables rapid pathogen-responsive maturation; computational modeling predicted that fibroblasts engineered to express DC-like IκB profiles show DC-like RelB control.","method":"Genetic mouse models (IκBα-KO, IκBɛ-KO, p52-KO); ChIP; Western blot; computational modeling of NF-κB signaling module; engineered fibroblast DC-like IκB reconstitution","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic KO models, ChIP, computational + experimental validation in engineered cells","pmids":["23086447"],"is_preprint":false},{"year":2012,"finding":"LTβR signaling activates the NF-κB2–RelB pathway in adipocyte precursor mesenchymal cells, blocking adipogenesis (suppressing Pparγ and Cebpα expression) and redirecting differentiation toward lymph node stromal cells during embryonic lymph node development.","method":"LTβR-KO and NF-κB2/RelB pathway genetic models; in vivo organogenesis assay; transplantation of embryonic adipocyte precursors into newborn lymph nodes; RT-PCR for adipogenic markers","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic models and in vivo organogenesis, single lab","pmids":["22940098"],"is_preprint":false},{"year":2012,"finding":"Hypercapnia (elevated CO2) induces cleavage of RelB to a lower-molecular-weight form and promotes its nuclear translocation in mouse embryonic fibroblasts and human pulmonary epithelial cells (A549); this processing is sensitive to proteasomal inhibition (MG-132) but independent of GSK3β or MALT1 activity.","method":"Western blot for RelB cleavage product; nuclear fractionation; proteasome inhibitor (MG-132); GSK3β inhibitor; MALT1 deficiency; in vivo hypercapnia lung injury model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic dissection of cleavage mechanism with in vivo correlation, single lab","pmids":["22396550"],"is_preprint":false},{"year":2014,"finding":"RelB directly targets the Runx2 promoter to inhibit its activation, thereby negatively regulating osteoblast differentiation and bone formation; RelB-KO mice develop increased trabecular bone mass with age and enhanced osteoblast differentiation associated with increased Runx2.","method":"RelB-KO mice; ChIP at Runx2 promoter; reporter assays; in vitro osteoblast differentiation; tibial bone defect transplantation model","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with KO phenotype and in vivo bone defect model, single lab","pmids":["24115294"],"is_preprint":false},{"year":2015,"finding":"An HDAC4–RelB–p52 complex maintains repressive chromatin around proapoptotic genes Bim and BMF in multiple myeloma; disruption of the RelB–HDAC4 interaction (by an HDAC4-mimetic polypeptide) blocks MM growth; RelB–p52 also represses BMF translation by regulating miR-221 expression; RelB is constitutively phosphorylated by ERK1 in MM, and phospho-RelB remains nuclear and is essential for Bim repression.","method":"Co-immunoprecipitation (HDAC4–RelB); ChIP at Bim/BMF promoters; HDAC4-mimetic polypeptide disruption; ERK1 kinase assay; siRNA for ERK1; reporter assays; in vivo xenograft growth assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — co-IP, ChIP, kinase assay identifying ERK1 as RelB kinase, peptide disruption with functional growth readout, multiple orthogonal methods","pmids":["26455434"],"is_preprint":false},{"year":2015,"finding":"RelB/p50 complexes (not p65) directly bind to the YKL-40 promoter in astrocytes and are required for cytokine-driven (IL-1 + oncostatin M) YKL-40 expression; IL-1 promotes RelB/p50 complex formation further enhanced by oncostatin M; dominant-negative IκBα but not p65 depletion inhibits YKL-40.","method":"ChIP at YKL-40 promoter; reporter assays with NF-κB site mutagenesis; p65 siRNA vs RelB/p50 manipulation; co-immunoprecipitation of RelB/p50; primary human and mouse astrocytes","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, co-IP, promoter mutagenesis, and siRNA in primary cells, single lab","pmids":["25681350"],"is_preprint":false},{"year":2016,"finding":"PAK4 phosphorylates RelB at Ser151, which is critical for RelB–DNA interaction and transcriptional activity; PAK4–RelB–C/EBPβ axis controls senescence-like growth arrest in breast cancer cells; loss of PAK4 increases RELB-driven C/EBPβ expression and triggers senescence.","method":"PAK4 kinase assay on RelB; phospho-mutant RelB (S151A); ChIP; siRNA/shRNA knockdown; mammary tumorigenesis in MMTV-PAK4 and MMTV-PyMT mouse models; senescence assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — kinase assay identifying PAK4 as RelB Ser151 kinase, mutagenesis with DNA binding/transcription readout, in vivo mouse models","pmids":["31399573"],"is_preprint":false},{"year":2016,"finding":"Relb acts downstream of SSEA-1+ mTEC stem cells and is necessary for effective production of RANK+ mTEC progenitors; SSEA-1+ mTEC stem cells are present in Relb-KO mice (demonstrating mTEC lineage specification is Relb-independent), but downstream RANK+ progenitor emergence requires Relb.","method":"RANK Venus reporter mice; Relb-KO and nude (Foxn1-KO) mice; flow cytometry for RANK/SSEA-1 co-expression; histological analysis of thymus development","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with stage-specific developmental readout using reporter mice, single lab","pmids":["26806881"],"is_preprint":false},{"year":2017,"finding":"DeficiencyofRelB in nonhematopoietic stromal cells (extrinsic) rather than cDC intrinsic mechanisms accounts for myeloid expansion and most cDC development defects in Relb-KO mice; cell-intrinsic RelB is required specifically for the Notch2- and LTβR-dependent splenic CD4+ cDC2 subset.","method":"Radiation chimeras (wild-type vs Relb-KO bone marrow in Relb-KO vs WT hosts); flow cytometry for DC subsets; conditional analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic series of reciprocal radiation chimeras cleanly dissecting cell-intrinsic vs extrinsic requirements","pmids":["28348230"],"is_preprint":false},{"year":2018,"finding":"RELB nuclear translocation in cholangiocytes is required for the ductular reaction and biliary fibrosis downstream of CYLD loss; LTβ–RELB axis promotes cholangiocyte proliferation; genetic co-deletion of Relb with Cyld in liver parenchymal cells abolishes ductular reaction, oval cell activation, and biliary fibrosis.","method":"Genetic double-KO mice (Cyld/RelbΔLPC); DDC diet model; siRNA knockdown of RELB in human cholangiocytes + LTβR agonist; ChIP; IHC; in situ hybridization","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-KO epistasis with in vitro siRNA rescue, multiple disease models","pmids":["30445013"],"is_preprint":false},{"year":2018,"finding":"GSK3β modulates RelB degradation via BCL10 phosphorylation; GSK3β inhibition or knockdown reduces MALT1-dependent proteolysis of RelB (and other MALT1 substrates) by diminishing CBM complex formation; this links GSK3β to the control of MALT1-mediated RelB cleavage in T cell activation.","method":"GSK3β pharmacologic inhibitors (SB216763, SB415286); siRNA knockdown; Western blot for RelB proteolysis; NF-κB reporter assay; co-immunoprecipitation of CBM complex","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic inhibition with co-IP and functional readouts, single lab","pmids":["29358699"],"is_preprint":false},{"year":2022,"finding":"RelB transcriptionally upregulates PD-L1 (CD274) by binding to a proximal NF-κB enhancer element in the CD274 promoter; RelB silencing in prostate cancer cells reduces PD-L1 expression and enhances susceptibility to CD4+/CD8+ T cell killing in vitro and in vivo.","method":"ChIP at CD274 promoter; reporter assays with promoter mutagenesis; siRNA/shRNA knockdown of RelB; T cell co-culture cytotoxicity assays; in vivo xenograft and metastasis models","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, promoter mutagenesis, and functional T cell killing assay with in vivo validation, single lab","pmids":["35177112"],"is_preprint":false},{"year":2023,"finding":"RelB confers tamoxifen resistance in breast cancer by transcriptionally upregulating GPX4, thereby inhibiting ferroptosis; elevated RelB–GPX4 axis in TAM-resistant cells alleviates TAM-induced ROS accumulation and ferroptotic cell death; suppression of RelB or GPX4 resensitizes resistant cells to tamoxifen in vitro and in vivo.","method":"ChIP at GPX4 promoter; reporter assays; siRNA/shRNA knockdown of RelB and GPX4; ferroptosis assays (lipid ROS, cell death markers); in vivo xenograft models","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, siRNA, and in vivo xenograft, single lab","pmids":["37944384"],"is_preprint":false}],"current_model":"RelB is an NF-κB family transcription factor that functions primarily as a heterodimer (with p50 or p52) to activate κB-dependent gene transcription via a C-terminal transactivation domain; it is held inactive in the cytoplasm by p100, which acts as a dedicated IκB, and is released by NIK/IKKα-dependent p100 processing in the alternative (noncanonical) NF-κB pathway; RelB can also form transcriptionally inactive complexes with RelA to dampen canonical NF-κB responses; it undergoes signal-specific phosphorylation (at Thr84/Ser552 by T cell signals, Ser151 by PAK4, and Ser368 for dimerization) and proteasomal degradation, as well as cleavage by MALT1 paracaspase after Arg-85; RelB is stabilized by interaction with p100/p52 through unique multi-domain contacts; in dendritic cells it drives maturation and antigen-presenting function, in osteoclast precursors it is required downstream of NIK for differentiation, in stromal cells it controls lymphoid organ microarchitecture and homing chemokine expression, and in cancer cells it drives resistance to therapy by upregulating MnSOD, GPX4, and PD-L1, among other targets."},"narrative":{"mechanistic_narrative":"RelB is an NF-κB family transcription factor that controls immune organ development, dendritic cell and osteoclast differentiation, and stress/cancer gene programs through κB-dependent transcription [PMID:1732739, PMID:7834753, PMID:7845467, PMID:18322009]. It carries a C-terminal transactivation domain and cannot bind κB DNA as a monomer; instead it forms transactivating heterodimers with p50 and p52, with crystallographic work showing p52:RelB engages a broader spectrum of κB sites (including AT-rich elements) than p50:RelA via RelB Arg125 [PMID:1732739, PMID:8183565, PMID:19098713]. RelB is held inactive in the cytosol through direct association with the NF-κB2 precursor p100, which acts as a dedicated IκB-like inhibitor via a region encompassing a nuclear export signal; NIK/IKKα-dependent p100 processing in the noncanonical (LTβR-driven) pathway releases p52:RelB for nuclear import through RelB's own bipartite NLS and importin α5/α6 [PMID:11687592, PMID:12709443, PMID:12505990, PMID:18462924]. RelB also forms transcriptionally inactive complexes with RelA/p65 that fail to bind κB DNA and dampen canonical NF-κB responses, a mechanism exploited during endotoxin tolerance [PMID:12657634, PMID:16951372]. Its activity is shaped by signal-specific post-translational control: phosphorylation at Thr84/Ser552 triggers proteasomal degradation after T-cell activation, MALT1 cleaves RelB after Arg-85 to license canonical NF-κB DNA binding, PAK4 phosphorylates Ser151 and ERK1 phosphorylation sustains nuclear RelB activity, and Ser368 governs dimerization [PMID:12874295, PMID:11781828, PMID:21873235, PMID:26455434, PMID:31399573]. Developmentally, RelB acts largely in radiation-resistant stromal cells to build splenic germinal centers, follicular dendritic cell networks, marginal zones, thymic medulla and lymph-node stroma, and to drive homing chemokine expression, while acting downstream of NIK in osteoclast precursors and as a direct Runx2 repressor in osteoblasts [PMID:7834753, PMID:7845467, PMID:11489970, PMID:18322009, PMID:22940098, PMID:24115294, PMID:28348230]. RelB pairs with the aryl hydrocarbon receptor to drive non-canonical target genes including IL-8, BAFF and BLC, and recruits chromatin regulators such as Daxx/Dnmt1 and HDAC4 to repress target loci [PMID:17823304, PMID:17900530, PMID:18413714, PMID:26455434]. In cancer it functions as a survival and resistance factor, transcriptionally upregulating MnSOD, PD-L1 (CD274), GPX4, and Bcl-2 to confer radioresistance, immune evasion, ferroptosis resistance, and an invasive phenotype [PMID:16261162, PMID:17369819, PMID:35177112, PMID:37944384].","teleology":[{"year":1992,"claim":"Established that RelB is a transactivator rather than an inhibitor, defining its core biochemical mode as a heterodimer-dependent activator of κB transcription.","evidence":"GAL4-RelB fusion activation assays, EMSA, and reporter assays showing RelB requires p50 heterodimerization to bind κB sites","pmids":["1732739"],"confidence":"High","gaps":["Did not define which physiological signals control RelB dimer formation","Did not address p52 partnering or in vivo relevance"]},{"year":1994,"claim":"Confirmed that human RelB behaves like its murine counterpart, forming transactivating heterodimers with p50 and p52, extending the activator model across species.","evidence":"Transfection reporter assays and EMSA of human RelB (I-Rel) heterodimeric complexes","pmids":["8183565"],"confidence":"Medium","gaps":["Single lab, did not address regulation or knockout phenotype","p52 vs p50 functional differences not resolved"]},{"year":1995,"claim":"Demonstrated the non-redundant in vivo role of RelB in thymic medulla and dendritic cell development, linking the transcription factor to immune homeostasis.","evidence":"relB germline knockout mice with EMSA, histology, and contact sensitivity assays; replicated by an independent lab","pmids":["7834753","7845467"],"confidence":"High","gaps":["Did not distinguish cell-intrinsic from cell-extrinsic requirements","Molecular target genes underlying phenotypes unknown"]},{"year":1996,"claim":"Showed the inflammatory and myeloid phenotypes of RelB-deficient mice are T-cell dependent, reframing the defect as dysregulated immune cross-talk rather than a purely cell-autonomous lesion.","evidence":"Genetic epistasis with RelB-KO × RAG-1-KO and RelB-KO × Nur77-Tg double-mutant mice","pmids":["8892630"],"confidence":"High","gaps":["Did not identify the stromal vs hematopoietic source of the requirement","Mechanism of aberrant T-cell activation unresolved"]},{"year":1997,"claim":"Identified RelB as a negative regulator of chemokine expression in fibroblasts, revealing a repressive arm of its activity distinct from transactivation.","evidence":"LPS stimulation of RelB-KO fibroblasts with EMSA, chemokine quantification, and RelB cDNA rescue plus in vivo recruitment assay","pmids":["9250151"],"confidence":"High","gaps":["Mechanism of chemokine repression (dimer composition) not defined","Did not identify direct promoter targets"]},{"year":2001,"claim":"Defined p100 as the dedicated cytoplasmic inhibitor of RelB and tied its release to NIK/IKKα-driven p100 processing, establishing RelB as the effector of the noncanonical pathway.","evidence":"Co-IP, nuclear fractionation, p100 deletion mapping, and NIK overexpression","pmids":["11687592"],"confidence":"High","gaps":["Did not resolve how RelB selects p50 vs p52 partners after release","Kinetics of processing in physiological signaling not addressed"]},{"year":2001,"claim":"Showed RelB is a transcriptional target of RelA, explaining the delayed kinetics of RelB activity as transcriptional induction rather than IκB-mediated retention.","evidence":"RELB promoter cloning, EMSA at κB sites, and TNF/LPS time-course with nuclear fractionation","pmids":["11753650"],"confidence":"High","gaps":["Did not address additional promoter inputs (AP-1, hormone receptors)","Cross-talk with p100-mediated retention not integrated"]},{"year":2001,"claim":"Mapped Ser368 as essential for RelB dimerization and showed RelB feedback-inhibits its own p100 processing, revealing a self-limiting regulatory loop.","evidence":"Site-directed mutagenesis (S368A/D), co-IP, and pulse-chase of p100 stability in plasmacytoma cells","pmids":["12874295"],"confidence":"Medium","gaps":["Single lab","Physiological consequence of the feedback loop in vivo untested"]},{"year":2001,"claim":"Established signal-specific proteasomal turnover of RelB driven by Thr84/Ser552 phosphorylation upon T-cell activation, introducing degradative control of RelB stability.","evidence":"T84A/S552A phosphosite mutagenesis, proteasome inhibition, and TCR/TPA stimulation of T cells","pmids":["11781828"],"confidence":"High","gaps":["Kinase(s) for Thr84/Ser552 not identified","Relationship to the later-defined N-terminal MALT1 cleavage unclear"]},{"year":2003,"claim":"Distinguished two p100-based mechanisms for signal-specific RelB control — IKKα-dependent processing under LTβR vs TNF-induced p100–RelB/p50 sequestration — clarifying how distinct stimuli route RelB.","evidence":"IKK and RelA knockout MEFs with EMSA and Co-IP under LTβR vs TNF stimulation; complementary NIK/NF-κB2 knockout in vivo work","pmids":["12709443","12505990"],"confidence":"High","gaps":["Did not define molecular basis of TNF-induced sequestration","Cell-type specificity of the two mechanisms unresolved"]},{"year":2003,"claim":"Identified inhibitory RelA·RelB heterodimers that cannot bind κB DNA, providing a mechanism by which RelB restrains canonical NF-κB output.","evidence":"Reporter assays, EMSA with in vitro translated proteins, Co-IP, and RelB overexpression in MEFs","pmids":["12657634"],"confidence":"High","gaps":["In vivo significance and stoichiometry of the dimer not established","Structural basis of DNA-binding incompetence not defined"]},{"year":2003,"claim":"Showed RelB requires stromal-cell expression to build germinal centers, FDC networks, and marginal zones, separating cell-extrinsic architectural roles from hematopoietic functions.","evidence":"Reciprocal bone marrow chimeras, immunofluorescence, and chemokine RT-PCR in RelB-KO spleen","pmids":["11489970"],"confidence":"High","gaps":["Direct stromal target genes beyond BLC not mapped","Mechanism of FDC patterning unresolved"]},{"year":2003,"claim":"Demonstrated RelB acts in stromal cells downstream of NIK for dendritic cell-mediated NKT cell development, providing in vivo genetic evidence for a NIK–RelB axis.","evidence":"RelB-KO and aly/aly NIK-mutant mice, bone marrow chimeras, compound heterozygous epistasis, and in vitro NIK kinase assay","pmids":["12810685"],"confidence":"High","gaps":["Direct NIK phosphorylation target in the pathway not pinpointed","Stromal RelB target genes for NKT development unknown"]},{"year":2003,"claim":"Showed RelB transcription is directly repressed by vitamin D via VDR·RXRα binding to relB promoter VDREs, identifying a hormonal brake on RelB independent of NF-κB signaling.","evidence":"VDRE identification, gel shift, reporter assays with VDRE mutagenesis, and VDR-KO mouse comparison","pmids":["14507914"],"confidence":"High","gaps":["Did not yet define the chromatin co-repressor machinery","Physiological context of vitamin D repression unaddressed"]},{"year":2005,"claim":"Defined the chromatin mechanism of vitamin D repression of RelB as VDR-recruited HDAC3, connecting hormonal signaling to histone deacetylation at the relB promoter.","evidence":"ChIP, HDAC inhibitor assays, HDAC3 overexpression/knockdown, and in vivo VDR-KO mice","pmids":["16239345"],"confidence":"High","gaps":["Did not address LPS-induced reversal mechanism in detail","Generalizability beyond dendritic cells unknown"]},{"year":2006,"claim":"Linked IKKα-driven p52/RelB transcription to cell-cycle control via Skp2/p27Kip1, extending RelB function into proliferation in cancer cells.","evidence":"IKKα siRNA, ChIP at the skp2 promoter, reporter assays, and cell cycle analysis in pancreatic cancer cells","pmids":["16902410"],"confidence":"Medium","gaps":["Single lab","Direct RelB occupancy vs IKKα-mediated indirect effects not fully separated"]},{"year":2006,"claim":"Identified RelB as a driver of antioxidant defense and radioresistance through MnSOD upregulation, establishing a cytoprotective role in cancer therapy resistance.","evidence":"Dominant-negative p100, RelB siRNA, MnSOD Western blot, and clonogenic radiation survival assay in prostate cancer cells","pmids":["16261162"],"confidence":"Medium","gaps":["Direct RelB binding at the MnSOD promoter not shown here","Single lab"]},{"year":2006,"claim":"Showed RelB induction during endotoxin tolerance represses proinflammatory genes via inactive p65/RelB dimers, providing a mechanistic basis for tolerance.","evidence":"THP-1 tolerance model with RelB siRNA rescue, Co-IP of p65/RelB, EMSA, and reporter assays","pmids":["16951372"],"confidence":"Medium","gaps":["Single lab","Genome-wide scope of RelB-mediated repression undefined"]},{"year":2007,"claim":"Discovered the RelB–AhR complex binding novel response elements to drive IL-8 and immune genes, revealing a non-canonical, ARNT-independent transcriptional partnership.","evidence":"Reciprocal Co-IP, ChIP at IL-8 promoter, reporter assays, PKA modulation, and EMSA; corroborated by AhR/RelB occupancy on BAFF, BLC, CCL1, IRF3 promoters","pmids":["17823304","17900530"],"confidence":"High","gaps":["Stoichiometry and DNA-binding subunit of the RelB/AhR complex unresolved","Physiological xenobiotic contexts incompletely defined"]},{"year":2007,"claim":"Defined constitutive RelB synthesis in ERα-negative breast cancer via NF-κB/AP-1 promoter synergy and its pro-invasive output through Bcl-2, embedding RelB in tumor aggressiveness.","evidence":"EMSA, ChIP, promoter mutagenesis reporters, siRNA, invasion assays, and breast tumor IHC correlation","pmids":["17369819"],"confidence":"High","gaps":["Did not establish the ERα-RelB reciprocal loop mechanism (addressed later)","Single tumor type"]},{"year":2008,"claim":"Provided the structural basis for RelB's distinct DNA-site preference, showing p52:RelB accommodates AT-rich κB sites via Arg125, explaining target-gene selectivity.","evidence":"X-ray crystallography of the p52:RelB:κB DNA complex with Arg125A mutagenesis, EMSA, and reporter assays","pmids":["19098713"],"confidence":"High","gaps":["Structure of RelB with other partners (RelA, p50) not solved","Genome-wide consequences of broadened site preference untested"]},{"year":2008,"claim":"Defined RelB's intrinsic bipartite NLS and importin α5/α6 usage, showing RelB nuclear import drives p52/RelB translocation independent of the p52 NLS.","evidence":"In vitro importin binding assays and NLS-mutant RelB nuclear translocation assays","pmids":["18462924"],"confidence":"Medium","gaps":["Single lab","Regulation of NLS exposure by p100 not mechanistically linked"]},{"year":2008,"claim":"Showed RelB stability depends on multi-domain contacts with p100/p105/p52/p50, establishing that the same precursor proteins both inhibit and protect RelB.","evidence":"Co-IP, domain mapping of p100 and RelB, and Western blot in p100-KO and p100/p105 double-KO cells","pmids":["18321863"],"confidence":"High","gaps":["Quantitative contribution of each domain to half-life not defined","Link between stabilization and degradative phosphorylation pathways unresolved"]},{"year":2008,"claim":"Identified Daxx/Dnmt1-mediated DNA hypermethylation as a RelB-dependent mechanism for epigenetic silencing of RelB target genes, expanding RelB into chromatin-level gene control.","evidence":"ChIP, bisulfite methylation analysis, daxx-KO/relB-KO cells with rescue, and Daxx/Dnmt1 Co-IP","pmids":["18413714"],"confidence":"High","gaps":["Signals controlling Daxx recruitment to RelB sites unknown","Generality across RelB target sets undefined"]},{"year":2008,"claim":"Established RelB as the essential NF-κB effector downstream of NIK for osteoclast differentiation, with p100 deletion bypassing the NIK requirement.","evidence":"NIK-KO/RelB-KO mice, p100-KO epistasis, retroviral RelB vs p65 rescue, osteoclast differentiation assays, and in vivo TNFα challenge","pmids":["18322009"],"confidence":"High","gaps":["Direct RelB osteoclastogenic target genes not mapped here","Dimer partner in osteoclast precursors not defined"]},{"year":2009,"claim":"Defined the reciprocal RelB–ERα antagonism via RelB-induced Blimp1 repression of ESR1, mechanistically connecting RelB activation to estrogen-independent breast cancer.","evidence":"RelB siRNA, ESR1/PRDM1 reporter assays, ChIP, and migration assays in breast cancer lines","pmids":["19433448"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect RelB control of PRDM1 not fully resolved"]},{"year":2010,"claim":"Identified REQ/DPF2 as an adaptor linking p52 to the Brm SWI/SNF complex at the BLC promoter, showing RelB/p52 recruits chromatin-remodeling machinery for target activation.","evidence":"In vitro binding, Co-IP, ChIP at the BLC promoter, REQ/Brm knockdown, and soft-agar growth assay","pmids":["20460684"],"confidence":"Medium","gaps":["Single lab","Generality of REQ-dependent remodeling across RelB targets untested"]},{"year":2011,"claim":"Discovered MALT1 cleavage of RelB after Arg-85 as a switch that licenses canonical NF-κB DNA binding, mechanistically integrating RelB into lymphoma signaling.","evidence":"In vitro MALT1 cleavage assay with MS site identification, proteasome rescue, and RelB overexpression in DLBCL lines with reporter/EMSA","pmids":["21873235"],"confidence":"High","gaps":["Upstream regulators of MALT1-RelB cleavage only partly defined","In vivo physiological scope beyond DLBCL unaddressed"]},{"year":2012,"claim":"Revealed that during DC activation RelB operates as a canonical-IκB-controlled RelB–p50 dimer rather than the expected p52 effector, refining the pathway logic of RelB control.","evidence":"IκBα-KO, IκBε-KO, p52-KO mice, ChIP, Western blot, and computational modeling validated in engineered fibroblasts","pmids":["23086447"],"confidence":"High","gaps":["Cell types where RelB-p52 dominates vs RelB-p50 not fully delineated","Quantitative dimer partitioning in vivo unresolved"]},{"year":2012,"claim":"Showed the NF-κB2–RelB pathway blocks adipogenesis and redirects mesenchymal precursors toward lymph-node stroma, extending RelB into stromal cell-fate decisions.","evidence":"LTβR-KO and NF-κB2/RelB genetic models with in vivo organogenesis and precursor transplantation assays","pmids":["22940098"],"confidence":"Medium","gaps":["Single lab","Direct RelB target genes controlling adipogenic suppression not mapped"]},{"year":2012,"claim":"Identified hypercapnia-induced proteasome-dependent RelB cleavage independent of GSK3β/MALT1, indicating a distinct stimulus-specific processing route.","evidence":"Western blot for cleavage product, nuclear fractionation, MG-132, GSK3β inhibitor, MALT1 deficiency, and in vivo lung injury model","pmids":["22396550"],"confidence":"Medium","gaps":["Protease responsible for hypercapnia-induced cleavage unidentified","Functional transcriptional consequences not fully defined"]},{"year":2014,"claim":"Established RelB as a direct repressor of Runx2 limiting osteoblast differentiation, complementing its osteoclast role to define bidirectional control of bone.","evidence":"RelB-KO mice, ChIP at the Runx2 promoter, reporter assays, osteoblast differentiation, and bone defect transplantation","pmids":["24115294"],"confidence":"Medium","gaps":["Single lab","Dimer partner mediating Runx2 repression not identified"]},{"year":2015,"claim":"Defined an HDAC4–RelB–p52 repressive complex sustaining myeloma survival via Bim/BMF silencing and identified ERK1 as a RelB kinase maintaining nuclear activity, adding a kinase-driven survival mechanism.","evidence":"HDAC4–RelB Co-IP, ChIP at Bim/BMF, HDAC4-mimetic peptide disruption, ERK1 kinase assay, and xenograft growth assay","pmids":["26455434"],"confidence":"High","gaps":["ERK1 phosphosite on RelB not specified","Generality of HDAC4-RelB axis beyond myeloma unknown"]},{"year":2015,"claim":"Showed RelB/p50 (not p65) directly drives cytokine-induced YKL-40 expression in astrocytes, demonstrating RelB-specific transcriptional control in CNS inflammation.","evidence":"ChIP at the YKL-40 promoter, NF-κB-site mutagenesis reporters, p65 vs RelB/p50 manipulation, and Co-IP in primary astrocytes","pmids":["25681350"],"confidence":"Medium","gaps":["Single lab","Upstream signaling controlling RelB/p50 formation only partly defined"]},{"year":2016,"claim":"Identified PAK4-mediated Ser151 phosphorylation as critical for RelB DNA binding, linking a kinase to RelB transcriptional activity and senescence control in breast cancer.","evidence":"PAK4 kinase assay on RelB, S151A phospho-mutant, ChIP, knockdowns, and MMTV-PAK4/PyMT mouse models","pmids":["31399573"],"confidence":"High","gaps":["Interplay between Ser151, Ser368, and degradative phosphosites unresolved","Tissue scope of PAK4-RelB axis beyond breast not defined"]},{"year":2016,"claim":"Showed Relb acts downstream of mTEC stem cells to generate RANK+ mTEC progenitors, refining its developmental position in thymic epithelial differentiation.","evidence":"RANK Venus reporter and Relb-KO/nude mice with flow cytometry and thymic histology","pmids":["26806881"],"confidence":"Medium","gaps":["Single lab","Direct RelB target genes in mTEC progenitor emergence unknown"]},{"year":2017,"claim":"Dissected cell-intrinsic vs extrinsic RelB requirements in cDC development, attributing most defects to stromal RelB while assigning intrinsic RelB to a specific cDC2 subset.","evidence":"Systematic reciprocal radiation chimeras with DC-subset flow cytometry","pmids":["28348230"],"confidence":"High","gaps":["Stromal RelB target genes governing DC homeostasis not mapped","Molecular basis of the Notch2/LTβR-dependent cDC2 requirement undefined"]},{"year":2018,"claim":"Established the LTβ–RELB axis as the driver of cholangiocyte ductular reaction and biliary fibrosis downstream of CYLD loss, extending RelB into liver disease pathology.","evidence":"Cyld/Relb double-KO mice, DDC diet model, RELB siRNA in human cholangiocytes with LTβR agonist, and ChIP","pmids":["30445013"],"confidence":"High","gaps":["Direct RelB fibrogenic target genes not detailed","Translational relevance to human cholangiopathies untested"]},{"year":2018,"claim":"Linked GSK3β to RelB turnover through BCL10 phosphorylation and CBM complex assembly, identifying an upstream modulator of MALT1-mediated RelB cleavage.","evidence":"GSK3β inhibitors and siRNA, Western blot for RelB proteolysis, NF-κB reporters, and CBM complex Co-IP","pmids":["29358699"],"confidence":"Medium","gaps":["Single lab","Direct GSK3β substrate phosphosite on BCL10 vs other CBM components not fully resolved"]},{"year":2022,"claim":"Identified RelB as a direct transcriptional activator of PD-L1, establishing a mechanism for RelB-driven tumor immune evasion.","evidence":"ChIP at CD274 promoter, promoter-mutagenesis reporters, RelB knockdown, T-cell co-culture cytotoxicity, and xenograft/metastasis models","pmids":["35177112"],"confidence":"Medium","gaps":["Single lab","Dimer partner driving CD274 transcription not defined"]},{"year":2023,"claim":"Showed RelB confers tamoxifen resistance by upregulating GPX4 and suppressing ferroptosis, linking RelB to redox-dependent therapy resistance.","evidence":"ChIP at GPX4 promoter, reporter assays, RelB/GPX4 knockdown, ferroptosis assays, and xenograft models","pmids":["37944384"],"confidence":"Medium","gaps":["Single lab","Upstream signals activating RelB in resistant cells not defined"]},{"year":null,"claim":"How the multiple phosphorylation marks (Thr84/Ser552, Ser151, Ser368, ERK1 sites), MALT1 cleavage, and p100-mediated stabilization are integrated into a single regulatory logic that selects RelB dimer partner, stability, and target-gene program in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTMs to dimer choice and target selection","Genome-wide RelB cistrome across cell types and stimuli not defined","Structural basis of RelA·RelB inactive dimers unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,23,21,41,42]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,23,35]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,24,30,39]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,11]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[30,34]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,23,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,10,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,7,12,38]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[26,31,33,37]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[25,28,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[18,21,41,42,39]}],"complexes":["RelB:p50 NF-κB heterodimer","RelB:p52 NF-κB heterodimer","RelB:RelA (inactive) heterodimer","HDAC4–RelB–p52 repressor complex"],"partners":["NFKB2/P100/P52","NFKB1/P50","RELA","AHR","HDAC4","DAXX","MALT1","DPF2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01201","full_name":"Transcription factor RelB","aliases":["I-Rel"],"length_aa":579,"mass_kda":62.1,"function":"NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed:26385063)","subcellular_location":"Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome","url":"https://www.uniprot.org/uniprotkb/Q01201/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RELB","classification":"Not Classified","n_dependent_lines":28,"n_total_lines":1208,"dependency_fraction":0.023178807947019868},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"NFKB1","stoichiometry":0.2},{"gene":"NFKB2","stoichiometry":0.2},{"gene":"RELA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/RELB","total_profiled":1310},"omim":[{"mim_id":"619289","title":"ZINC FINGER PROTEIN 91, ATYPICAL E3 UBIQUITIN LIGASE; ZFP91","url":"https://www.omim.org/entry/619289"},{"mim_id":"618638","title":"HECT DOMAIN E3 UBIQUITIN PROTEIN LIGASE 3; HECTD3","url":"https://www.omim.org/entry/618638"},{"mim_id":"617585","title":"IMMUNODEFICIENCY 53; IMD53","url":"https://www.omim.org/entry/617585"},{"mim_id":"616704","title":"COMM DOMAIN-CONTAINING PROTEIN 10; COMMD10","url":"https://www.omim.org/entry/616704"},{"mim_id":"616701","title":"COMM DOMAIN-CONTAINING PROTEIN 4; COMMD4","url":"https://www.omim.org/entry/616701"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RELB"},"hgnc":{"alias_symbol":["REL-B"],"prev_symbol":[]},"alphafold":{"accession":"Q01201","domains":[{"cath_id":"2.60.40.340","chopping":"127-294","consensus_level":"high","plddt":91.9372,"start":127,"end":294},{"cath_id":"2.60.40.10","chopping":"306-399","consensus_level":"high","plddt":96.6928,"start":306,"end":399}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01201","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01201-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01201-F1-predicted_aligned_error_v6.png","plddt_mean":68.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RELB","jax_strain_url":"https://www.jax.org/strain/search?query=RELB"},"sequence":{"accession":"Q01201","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01201.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01201/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01201"}},"corpus_meta":[{"pmid":"7834753","id":"PMC_7834753","title":"Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7834753","citation_count":687,"is_preprint":false},{"pmid":"7845467","id":"PMC_7845467","title":"Expression of relB is required for the development of thymic medulla and dendritic cells.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7845467","citation_count":636,"is_preprint":false},{"pmid":"1732739","id":"PMC_1732739","title":"RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1732739","citation_count":353,"is_preprint":false},{"pmid":"17823304","id":"PMC_17823304","title":"RelB, a new partner of aryl hydrocarbon receptor-mediated transcription.","date":"2007","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17823304","citation_count":265,"is_preprint":false},{"pmid":"3019679","id":"PMC_3019679","title":"Mechanism of postsegregational killing by the hok gene product of the parB system of plasmid R1 and its homology with the relF gene product of the E. coli relB operon.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3019679","citation_count":231,"is_preprint":false},{"pmid":"21873235","id":"PMC_21873235","title":"Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21873235","citation_count":190,"is_preprint":false},{"pmid":"17369819","id":"PMC_17369819","title":"Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.","date":"2007","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17369819","citation_count":181,"is_preprint":false},{"pmid":"11489970","id":"PMC_11489970","title":"Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11489970","citation_count":174,"is_preprint":false},{"pmid":"11753650","id":"PMC_11753650","title":"Transcription of the RelB gene is regulated by NF-kappaB.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11753650","citation_count":173,"is_preprint":false},{"pmid":"11687592","id":"PMC_11687592","title":"RelB cellular regulation and transcriptional activity are regulated by p100.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11687592","citation_count":168,"is_preprint":false},{"pmid":"12505990","id":"PMC_12505990","title":"RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12505990","citation_count":165,"is_preprint":false},{"pmid":"23086447","id":"PMC_23086447","title":"Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23086447","citation_count":156,"is_preprint":false},{"pmid":"18955032","id":"PMC_18955032","title":"A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18955032","citation_count":154,"is_preprint":false},{"pmid":"12717418","id":"PMC_12717418","title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12717418","citation_count":151,"is_preprint":false},{"pmid":"9250151","id":"PMC_9250151","title":"RelB regulation of chemokine expression modulates local inflammation.","date":"1997","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9250151","citation_count":142,"is_preprint":false},{"pmid":"8269849","id":"PMC_8269849","title":"Expression of relB transcripts during lymphoid organ development: specific expression in dendritic antigen-presenting cells.","date":"1993","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8269849","citation_count":137,"is_preprint":false},{"pmid":"12709443","id":"PMC_12709443","title":"RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12709443","citation_count":130,"is_preprint":false},{"pmid":"12657634","id":"PMC_12657634","title":"RelB forms transcriptionally inactive complexes with RelA/p65.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12657634","citation_count":126,"is_preprint":false},{"pmid":"18322009","id":"PMC_18322009","title":"RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18322009","citation_count":121,"is_preprint":false},{"pmid":"9378953","id":"PMC_9378953","title":"Nuclear localization of RelB is associated with effective antigen-presenting cell function.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9378953","citation_count":116,"is_preprint":false},{"pmid":"22940098","id":"PMC_22940098","title":"Lymphotoxin-β receptor signaling through NF-κB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells.","date":"2012","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22940098","citation_count":112,"is_preprint":false},{"pmid":"17442929","id":"PMC_17442929","title":"Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17442929","citation_count":112,"is_preprint":false},{"pmid":"19747491","id":"PMC_19747491","title":"RelB and RelE of Escherichia coli form a tight complex that represses transcription via the ribbon-helix-helix motif in RelB.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19747491","citation_count":104,"is_preprint":false},{"pmid":"12810685","id":"PMC_12810685","title":"NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12810685","citation_count":96,"is_preprint":false},{"pmid":"23999131","id":"PMC_23999131","title":"Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation.","date":"2013","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23999131","citation_count":94,"is_preprint":false},{"pmid":"18413714","id":"PMC_18413714","title":"Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18413714","citation_count":93,"is_preprint":false},{"pmid":"16951372","id":"PMC_16951372","title":"Induction of RelB participates in endotoxin tolerance.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16951372","citation_count":93,"is_preprint":false},{"pmid":"14507914","id":"PMC_14507914","title":"Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14507914","citation_count":91,"is_preprint":false},{"pmid":"16902410","id":"PMC_16902410","title":"IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16902410","citation_count":84,"is_preprint":false},{"pmid":"17900530","id":"PMC_17900530","title":"Involvement of RelB in aryl hydrocarbon receptor-mediated induction of chemokines.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17900530","citation_count":81,"is_preprint":false},{"pmid":"16261162","id":"PMC_16261162","title":"RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16261162","citation_count":78,"is_preprint":false},{"pmid":"18501926","id":"PMC_18501926","title":"Structural mechanism of transcriptional autorepression of the Escherichia coli RelB/RelE antitoxin/toxin module.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18501926","citation_count":76,"is_preprint":false},{"pmid":"16239345","id":"PMC_16239345","title":"Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16239345","citation_count":75,"is_preprint":false},{"pmid":"16081776","id":"PMC_16081776","title":"Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16081776","citation_count":74,"is_preprint":false},{"pmid":"18462924","id":"PMC_18462924","title":"NF-kappaB p52, RelB and c-Rel are transported into the nucleus via a subset of importin alpha molecules.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18462924","citation_count":73,"is_preprint":false},{"pmid":"19433448","id":"PMC_19433448","title":"RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19433448","citation_count":68,"is_preprint":false},{"pmid":"2990907","id":"PMC_2990907","title":"Sequence of the relB transcription unit from Escherichia coli and identification of the relB gene.","date":"1985","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2990907","citation_count":68,"is_preprint":false},{"pmid":"22968463","id":"PMC_22968463","title":"Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22968463","citation_count":67,"is_preprint":false},{"pmid":"26385063","id":"PMC_26385063","title":"The effects of RelB deficiency on lymphocyte development and function.","date":"2015","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/26385063","citation_count":66,"is_preprint":false},{"pmid":"24115294","id":"PMC_24115294","title":"NF-κB RelB negatively regulates osteoblast differentiation and bone formation.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24115294","citation_count":64,"is_preprint":false},{"pmid":"8892630","id":"PMC_8892630","title":"Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8892630","citation_count":64,"is_preprint":false},{"pmid":"19098713","id":"PMC_19098713","title":"NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19098713","citation_count":63,"is_preprint":false},{"pmid":"11781828","id":"PMC_11781828","title":"Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11781828","citation_count":62,"is_preprint":false},{"pmid":"37944384","id":"PMC_37944384","title":"RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37944384","citation_count":61,"is_preprint":false},{"pmid":"18321863","id":"PMC_18321863","title":"Stabilization of RelB requires multidomain interactions with p100/p52.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18321863","citation_count":61,"is_preprint":false},{"pmid":"21640702","id":"PMC_21640702","title":"Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression.","date":"2011","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/21640702","citation_count":58,"is_preprint":false},{"pmid":"23451236","id":"PMC_23451236","title":"The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23451236","citation_count":56,"is_preprint":false},{"pmid":"25681350","id":"PMC_25681350","title":"RelB/p50 complexes regulate cytokine-induced YKL-40 expression.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25681350","citation_count":55,"is_preprint":false},{"pmid":"15315978","id":"PMC_15315978","title":"RelB regulates human dendritic cell subset development by promoting monocyte intermediates.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15315978","citation_count":55,"is_preprint":false},{"pmid":"12727647","id":"PMC_12727647","title":"The role of relB in regulating the adaptive immune response.","date":"2003","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12727647","citation_count":54,"is_preprint":false},{"pmid":"26455434","id":"PMC_26455434","title":"Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26455434","citation_count":54,"is_preprint":false},{"pmid":"31151139","id":"PMC_31151139","title":"Role of NF-kB RelB in Aryl Hydrocarbon Receptor-Mediated Ligand Specific Effects.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31151139","citation_count":50,"is_preprint":false},{"pmid":"20649549","id":"PMC_20649549","title":"RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.","date":"2010","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20649549","citation_count":49,"is_preprint":false},{"pmid":"17367745","id":"PMC_17367745","title":"Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation.","date":"2007","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/17367745","citation_count":48,"is_preprint":false},{"pmid":"17327399","id":"PMC_17327399","title":"Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17327399","citation_count":48,"is_preprint":false},{"pmid":"10540217","id":"PMC_10540217","title":"Expression of the RelB transcription factor correlates with the activation of human dendritic cells.","date":"1999","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10540217","citation_count":48,"is_preprint":false},{"pmid":"17641044","id":"PMC_17641044","title":"Despite inhibition of nuclear localization of NF-kappa B p65, c-Rel, and RelB, 17-beta estradiol up-regulates NF-kappa B signaling in mouse splenocytes: the potential role of Bcl-3.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17641044","citation_count":48,"is_preprint":false},{"pmid":"20460684","id":"PMC_20460684","title":"Requiem protein links RelB/p52 and the Brm-type SWI/SNF complex in a noncanonical NF-kappaB pathway.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20460684","citation_count":47,"is_preprint":false},{"pmid":"12874295","id":"PMC_12874295","title":"Critical role of RelB serine 368 for dimerization and p100 stabilization.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12874295","citation_count":47,"is_preprint":false},{"pmid":"24752502","id":"PMC_24752502","title":"Aryl hydrocarbon receptor (AhR) attenuation of subchronic cigarette smoke-induced pulmonary neutrophilia is associated with retention of nuclear RelB and suppression of intercellular adhesion molecule-1 (ICAM-1).","date":"2014","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24752502","citation_count":47,"is_preprint":false},{"pmid":"26806881","id":"PMC_26806881","title":"Relb acts downstream of medullary thymic epithelial stem cells and is essential for the emergence of RANK(+) medullary epithelial progenitors.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26806881","citation_count":46,"is_preprint":false},{"pmid":"11027342","id":"PMC_11027342","title":"RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11027342","citation_count":46,"is_preprint":false},{"pmid":"23922380","id":"PMC_23922380","title":"RelB: an outlier in leukocyte biology.","date":"2013","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/23922380","citation_count":45,"is_preprint":false},{"pmid":"14627988","id":"PMC_14627988","title":"Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel-/- B cells.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14627988","citation_count":45,"is_preprint":false},{"pmid":"26773039","id":"PMC_26773039","title":"B-cell survival and development controlled by the coordination of NF-κB family members RelB and cRel.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26773039","citation_count":44,"is_preprint":false},{"pmid":"34232979","id":"PMC_34232979","title":"The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34232979","citation_count":43,"is_preprint":false},{"pmid":"27153093","id":"PMC_27153093","title":"Post-Translational Modifications of RelB NF-κB Subunit and Associated Functions.","date":"2016","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/27153093","citation_count":43,"is_preprint":false},{"pmid":"9209490","id":"PMC_9209490","title":"Thymocytes and RelB-dependent medullary epithelial cells provide growth-promoting and organization signals, respectively, to thymic medullary stromal cells.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9209490","citation_count":43,"is_preprint":false},{"pmid":"31277415","id":"PMC_31277415","title":"NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31277415","citation_count":42,"is_preprint":false},{"pmid":"11274135","id":"PMC_11274135","title":"Purification of the RelB and RelE proteins of Escherichia coli: RelE binds to RelB and to ribosomes.","date":"2001","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11274135","citation_count":42,"is_preprint":false},{"pmid":"17446175","id":"PMC_17446175","title":"CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17446175","citation_count":40,"is_preprint":false},{"pmid":"31399573","id":"PMC_31399573","title":"PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31399573","citation_count":38,"is_preprint":false},{"pmid":"22734038","id":"PMC_22734038","title":"RelB/NF-κB2 regulates corticotropin-releasing hormone in the human placenta.","date":"2012","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22734038","citation_count":38,"is_preprint":false},{"pmid":"19020113","id":"PMC_19020113","title":"RelB sustains IkappaBalpha expression during endotoxin tolerance.","date":"2008","source":"Clinical and vaccine immunology : CVI","url":"https://pubmed.ncbi.nlm.nih.gov/19020113","citation_count":37,"is_preprint":false},{"pmid":"22396550","id":"PMC_22396550","title":"Hypercapnia induces cleavage and nuclear localization of RelB protein, giving insight into CO2 sensing and signaling.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22396550","citation_count":37,"is_preprint":false},{"pmid":"35177112","id":"PMC_35177112","title":"RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35177112","citation_count":36,"is_preprint":false},{"pmid":"28108513","id":"PMC_28108513","title":"RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28108513","citation_count":36,"is_preprint":false},{"pmid":"19424026","id":"PMC_19424026","title":"Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury.","date":"2009","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19424026","citation_count":36,"is_preprint":false},{"pmid":"16107733","id":"PMC_16107733","title":"Regulation of RelB expression during the initiation of dendritic cell differentiation.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16107733","citation_count":34,"is_preprint":false},{"pmid":"26851215","id":"PMC_26851215","title":"Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-κB Transcription Factors RELB and NF-κB2 in B Cells.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26851215","citation_count":34,"is_preprint":false},{"pmid":"8183565","id":"PMC_8183565","title":"Human RelB (I-Rel) functions as a kappa B site-dependent transactivating member of the family of Rel-related proteins.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8183565","citation_count":34,"is_preprint":false},{"pmid":"22065573","id":"PMC_22065573","title":"Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22065573","citation_count":34,"is_preprint":false},{"pmid":"34198987","id":"PMC_34198987","title":"RelB and Neuroinflammation.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34198987","citation_count":32,"is_preprint":false},{"pmid":"18688039","id":"PMC_18688039","title":"RelB is differentially regulated by IkappaB Kinase-alpha in B cells and mouse lung by cigarette smoke.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18688039","citation_count":32,"is_preprint":false},{"pmid":"23394901","id":"PMC_23394901","title":"RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages.","date":"2013","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23394901","citation_count":32,"is_preprint":false},{"pmid":"23555623","id":"PMC_23555623","title":"Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555623","citation_count":32,"is_preprint":false},{"pmid":"33991110","id":"PMC_33991110","title":"Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33991110","citation_count":31,"is_preprint":false},{"pmid":"28348230","id":"PMC_28348230","title":"Deficiency of transcription factor RelB perturbs myeloid and DC development by hematopoietic-extrinsic mechanisms.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28348230","citation_count":31,"is_preprint":false},{"pmid":"32793229","id":"PMC_32793229","title":"17β-Estradiol Promotes Trained Immunity in Females Against Sepsis via Regulating Nucleus Translocation of RelB.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32793229","citation_count":30,"is_preprint":false},{"pmid":"32607691","id":"PMC_32607691","title":"Apigenin Modulates Dendritic Cell Activities and Curbs Inflammation Via RelB Inhibition in the Context of Neuroinflammatory Diseases.","date":"2020","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32607691","citation_count":29,"is_preprint":false},{"pmid":"15596805","id":"PMC_15596805","title":"Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15596805","citation_count":29,"is_preprint":false},{"pmid":"29358699","id":"PMC_29358699","title":"GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29358699","citation_count":28,"is_preprint":false},{"pmid":"17996728","id":"PMC_17996728","title":"In vitro selection of optimal RelB/p52 DNA-binding motifs.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17996728","citation_count":28,"is_preprint":false},{"pmid":"20686703","id":"PMC_20686703","title":"Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20686703","citation_count":27,"is_preprint":false},{"pmid":"30445013","id":"PMC_30445013","title":"Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.","date":"2018","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30445013","citation_count":27,"is_preprint":false},{"pmid":"27711077","id":"PMC_27711077","title":"RelB/NF-κB links cell cycle transition and apoptosis to endometrioid adenocarcinoma tumorigenesis.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27711077","citation_count":26,"is_preprint":false},{"pmid":"24042463","id":"PMC_24042463","title":"RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.","date":"2013","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/24042463","citation_count":26,"is_preprint":false},{"pmid":"19087315","id":"PMC_19087315","title":"Differential RelA- and RelB-dependent gene transcription in LTbetaR-stimulated mouse embryonic fibroblasts.","date":"2008","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19087315","citation_count":25,"is_preprint":false},{"pmid":"22395283","id":"PMC_22395283","title":"Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB.","date":"2012","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22395283","citation_count":24,"is_preprint":false},{"pmid":"27525719","id":"PMC_27525719","title":"G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway.","date":"2016","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27525719","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47039,"output_tokens":10911,"usd":0.152391,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22101,"output_tokens":10908,"usd":0.191603,"stage2_stop_reason":"end_turn"},"total_usd":0.343994,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"RelB contains a C-terminal transcriptional activation domain (last 180 amino acids) and does not bind NF-κB sites as a monomer, but forms heterodimers with p50-NF-κB that bind κB sites and transactivate κB-dependent promoters, unlike p50 homodimers which cannot transactivate.\",\n      \"method\": \"GAL4-RelB fusion transcriptional activation assays in yeast; EMSA; reporter gene (transactivation) assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (yeast transcriptional activation, EMSA, reporter assays) in founding characterization paper, replicated by subsequent work\",\n      \"pmids\": [\"1732739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Human RelB (I-Rel) forms κB-binding heterodimeric complexes with p50 and p52 that potently transactivate κB-dependent constructs; it functions as a transactivator, not an inhibitor, consistent with murine RelB.\",\n      \"method\": \"Transfection reporter assays; EMSA with heterodimeric complexes\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (EMSA + reporter), single lab\",\n      \"pmids\": [\"8183565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"RelB is required for development of thymic medulla and dendritic cells; germline disruption of relB results in absence of RelB protein, dramatic reduction of constitutive κB-binding activity in thymus/spleen, loss of thymic dendritic cells, multiorgan inflammation, myeloid hyperplasia, and impaired cellular immunity.\",\n      \"method\": \"Targeted gene disruption (knockout mouse); EMSA; histology; contact sensitivity assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple defined cellular phenotypes, replicated by independent lab (PMID:7845467)\",\n      \"pmids\": [\"7834753\", \"7845467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent: RelB-KO × RAG-1-KO and RelB-KO × Nur77/N10-Tg mice are disease-free; B cells are not required for the phenotype.\",\n      \"method\": \"Genetic epistasis using double-mutant mice (RelB-KO × RAG-1-KO; RelB-KO × Nur77/N10-Tg; RelB-KO × p50-KO); histology\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean epistasis with multiple double-mutant combinations, clear cellular phenotype readout\",\n      \"pmids\": [\"8892630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RelB is an important regulator of chemokine expression in fibroblasts: RelB-deficient fibroblasts show persistent, dramatically elevated expression of seven chemokines (RANTES, MIP-1α, MIP-1β, MIP-2, IP-10, JE/MCP-1, KC/CINC) after LPS stimulation, correlated with increased NF-κB binding; transfection of RelB cDNA into RelB-deficient fibroblasts reversed this overexpression.\",\n      \"method\": \"RelB-KO fibroblast LPS stimulation; EMSA; chemokine measurement; RelB cDNA rescue transfection; in vivo granulocyte recruitment assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function (rescue) with specific molecular readouts, in vitro and in vivo\",\n      \"pmids\": [\"9250151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RelB is associated in the cytosol with p100 (NF-κB2 precursor), not with IκBα, IκBβ, IκBε, or p105; p100 prevents RelB nuclear localization and transcriptional activity via amino acids 623–900 of p100, which contain a nuclear export signal; NF-κB-inducing kinase (NIK) overexpression, which promotes p100 processing via IKKα, induces RelB nuclear translocation.\",\n      \"method\": \"Co-immunoprecipitation; nuclear fractionation; reporter assays; structure–function analysis of p100 deletion mutants; NIK overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter assays, multiple orthogonal methods in single study\",\n      \"pmids\": [\"11687592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RelA alone is sufficient to induce RelB gene transcription via a TATA-less promoter containing two NF-κB binding sites; the delayed nuclear translocation of RelB after TNF or LPS stimulation is secondary to increased RelB transcription, not to IκB-mediated cytosolic retention.\",\n      \"method\": \"Promoter cloning; reporter assays; EMSA with promoter κB sites; TNF/LPS stimulation time-course; nuclear fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — promoter characterization with EMSA, reporter assays, and functional knockin/overexpression, multiple orthogonal methods\",\n      \"pmids\": [\"11753650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RelB is required for germinal center formation, follicular dendritic cell networks, and marginal zone organization in spleen; reciprocal bone marrow transfers demonstrate that RelB expression in radiation-resistant stromal cells (not hematopoietic cells) is required for GCs, FDC networks, and MZ structures, whereas RelB in hematopoietic cells is required for MZ B cell generation. RelB-dependent homing chemokine expression (especially BLC) is strongly reduced in RelB-deficient spleen.\",\n      \"method\": \"RelB-KO mice; reciprocal bone marrow chimeras; immunofluorescence; RT-PCR for chemokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal bone marrow transfers provide clean cell-extrinsic vs intrinsic dissection, multiple tissue/molecular readouts\",\n      \"pmids\": [\"11489970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RelB serine 368 is critical for dimerization with other NF-κB family members but not for nuclear import; expression of functional RelB strongly reduces p52 generation and increases expression of p100 precursor by prolonging p100 half-life, suggesting RelB inhibits p100 processing.\",\n      \"method\": \"Site-directed mutagenesis (S368A/D); co-immunoprecipitation; Western blot for p100/p52; pulse-chase analysis of p100 stability in S107 plasmacytoma cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with co-IP and pulse-chase, single lab\",\n      \"pmids\": [\"12874295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RelB undergoes signal-specific, proteasomal degradation upon T cell activation (TCR or TPA/ionomycin) but not TNFα stimulation; degradation proceeds through phosphorylation at Thr84 and Ser552, followed by an N-terminal cleavage, then complete proteasomal degradation; mutation of both phosphoacceptor sites stabilizes RelB.\",\n      \"method\": \"Phosphorylation site mutagenesis (T84A/S552A double mutant); Western blot; proteasome inhibitor treatment; TCR/TPA stimulation of T cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphosite mutagenesis with functional stabilization readout plus pharmacologic inhibition, single lab\",\n      \"pmids\": [\"11781828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LTβR signaling induces RelB/p50 and RelA/p50 heterodimers, whereas TNF activates only RelA/p50; LTβR-induced RelB/p50 binding requires p100 processing mediated by IKKα but not IKKβ, NEMO/IKKγ, or RelA; TNF increases p100–RelB/p50 nuclear association, specifically inhibiting RelB DNA binding, providing two distinct p100-dependent mechanisms for signal-specific RelB regulation.\",\n      \"method\": \"Deficient MEF cells (IKKα-KO, IKKβ-KO, IKKγ-KO, RelA-KO); EMSA; Co-IP; LTβR and TNF stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic KO cell systems with EMSA and co-IP, clean dissection of signaling requirements\",\n      \"pmids\": [\"12709443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RelB forms transcriptionally inactive heterodimers with RelA/p65; these RelA·RelB dimers are unable to bind κB DNA in vitro; overexpressed RelB significantly reduces TNFα-induced RelA activity; these complexes are not regulated by IκB proteins and are found in both cytoplasm and nucleus.\",\n      \"method\": \"Reporter gene assays; EMSA with in vitro translated proteins; co-immunoprecipitation; overexpression in MEFs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EMSA, reporter, co-IP), mechanistic characterization of a new dimer\",\n      \"pmids\": [\"12657634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LTβR signaling activates p52-RelB heterodimers via NIK- and IKKα-dependent (but IKKβ- and IKKγ-independent) processing of p100; TNF activates RelA but specifically inhibits RelB by increasing p100–RelB/p50 complex formation; RelB/p52 is required for Peyer's patch development downstream of LTβR.\",\n      \"method\": \"Knockout mice (NF-κB2-KO, RelB-KO, LTβR-KO, NIK-mutant); EMSA; Western blot for p100/p52; genetic epistasis in vivo\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, EMSA, and in vivo epistasis\",\n      \"pmids\": [\"12505990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RelB stabilizes itself through direct interaction with p100 (all domains engaged), p105, p52, and p50; p100–RelB complex formation requires unique N-terminal domain contacts and RelB's transcriptional activation domain interacting with p100's processing region; RelB protein levels are significantly reduced in the absence of p100 and further reduced when both p100 and p105 are absent.\",\n      \"method\": \"Co-immunoprecipitation; domain deletion/mutagenesis of p100 and RelB; Western blot in p100-KO and p100/p105-double-KO cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic domain mapping with reciprocal co-IP and genetic cell models, multiple orthogonal methods\",\n      \"pmids\": [\"18321863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RelB is the NF-κB subunit required for dendritic cell-mediated NKT cell development via a NIK-dependent pathway; RelB must be expressed in irradiation-resistant, CD1d-negative host stromal cells (not hematopoietic cells) for NKT cell development; compound heterozygous RelB+/− × aly/+ mice have reduced NKT cell responses, demonstrating in vivo genetic interaction between NIK and RelB.\",\n      \"method\": \"RelB-KO and NIK-mutant (aly/aly) mice; bone marrow chimeras; compound heterozygous epistasis; flow cytometry; in vitro NIK kinase assay with RelB activation readout\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bone marrow chimeras, compound heterozygous epistasis, and in vitro kinase signaling, multiple orthogonal approaches\",\n      \"pmids\": [\"12810685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"1α,25-dihydroxyvitamin D3 (and analogs) directly represses RelB transcription through VDR·RXRα binding to vitamin D response elements in the relB promoter; mutagenesis of these VDREs abolishes suppression; NF-κB response element mutagenesis does not affect vitamin D suppression, ruling out indirect NF-κB effects.\",\n      \"method\": \"Promoter VDRE identification; gel shift assays (VDR·RXRα binding); reporter assays with VDRE mutagenesis; VDR overexpression; DC-derived cell lines; in vivo VDR-KO mouse comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutagenesis, gel shift, reporter assays, in vivo VDR-KO confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"14507914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Vitamin D receptor-mediated relB promoter suppression in dendritic cells involves direct VDR binding to the relB promoter and recruitment of HDAC3 (but not HDAC1 alone); HDAC3 association is enhanced by D3 ligand and reduced by LPS; HDAC3 overexpression causes relB suppression, and HDAC3 depletion attenuates D3-mediated suppression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); HDAC inhibitor experiments; HDAC3 overexpression/siRNA knockdown; promoter reporter assays; in vivo VDR-KO mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, loss-of-function, gain-of-function, and in vivo genetic validation, multiple orthogonal methods\",\n      \"pmids\": [\"16239345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IKKα regulates G1-to-S phase progression in pancreatic cancer cells by controlling p52/RelB-dependent transcription of the skp2 gene, which in turn regulates Skp2-mediated degradation of p27Kip1; IKKα siRNA increases p27 protein by downregulating Skp2.\",\n      \"method\": \"IKKα-specific siRNA; Western blot for p27/Skp2; ChIP at skp2 promoter for RelB/p52; reporter assays; cell cycle analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, siRNA, and cell cycle readouts in single lab\",\n      \"pmids\": [\"16902410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RelB transcriptionally upregulates manganese superoxide dismutase (MnSOD) gene in aggressive prostate cancer cells; selective inhibition of RelB (by dominant-negative p100 mutant or siRNA) decreases MnSOD levels and significantly increases radiation sensitivity of prostate cancer cells.\",\n      \"method\": \"Dominant-negative p100 mutant; siRNA knockdown of RelB; Western blot for MnSOD; clonogenic radiation survival assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent inhibition approaches with functional radiosensitivity readout, single lab\",\n      \"pmids\": [\"16261162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RelB induction during LPS endotoxin tolerance represses proinflammatory gene expression (e.g., IL-1β, TNFα); tolerant cells form transcriptionally inactive NF-κB p65/RelB heterodimers; siRNA knockdown of RelB in tolerant THP-1 cells restores endotoxin induction of IL-1β.\",\n      \"method\": \"THP-1 endotoxin tolerance model; RelB siRNA; reporter assays; co-immunoprecipitation of p65/RelB complexes; EMSA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA rescue experiment, co-IP, and EMSA, single lab\",\n      \"pmids\": [\"16951372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RelB physically interacts with the aryl hydrocarbon receptor (AhR); the RelB/AhR complex binds a novel RelB/AhR responsive element in the IL-8 promoter (distinct from classical DRE or κB sites) as well as xenobiotic responsive elements; AhR ligand TCDD promotes time-dependent recruitment of AhR to the RelB/AhR element via protein kinase A; RelB markedly increases TCDD-induced XRE reporter activity.\",\n      \"method\": \"Co-immunoprecipitation (RelB–AhR); ChIP (time-dependent AhR recruitment to IL-8 promoter); reporter assays; PKA inhibitor/activator experiments; EMSA\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, ChIP, reporter assays, and pharmacologic modulation, multiple orthogonal methods\",\n      \"pmids\": [\"17823304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Constitutive de novo RelB synthesis in ERα-negative invasive breast cancer cells is driven by p50-p65 NF-κB and c-Jun–Fra-2 AP-1 complexes binding to the RELB promoter in synergy; ERα signaling inhibits RelB synthesis by reducing NF-κB and Fra-2 levels; RelB induces Bcl-2 to promote the invasive phenotype.\",\n      \"method\": \"EMSA; ChIP; reporter assays with promoter mutagenesis; siRNA knockdown; invasion assays; IHC correlation in breast cancer tissues\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, promoter mutagenesis, siRNA loss-of-function, and invasion phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"17369819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AhR/RelB complexes bind NF-κB elements on BAFF, BLC, CCL1, and IRF3 promoters in an ARNT-independent manner to drive their expression; TCDD induces this binding and gene expression in a RelB- and AhR-dependent manner in U937 macrophages.\",\n      \"method\": \"EMSA; ChIP; siRNA knockdown of AhR and RelB; RT-PCR for target gene expression; TCDD treatment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with EMSA and siRNA, single lab, multiple target genes\",\n      \"pmids\": [\"17900530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The NF-κB p52:RelB heterodimer crystal structure reveals Arg125 of RelB contacts an additional DNA base pair; p52:RelB Arg125A mutant shows defective DNA binding and transcriptional activity selectively at κB sites with contiguous central A:T base pairs; p52:RelB binds a broader spectrum of κB sites than p50:RelA due to its ability to accommodate structural variation at AT-rich sites.\",\n      \"method\": \"X-ray crystallography of p52:RelB:κB DNA complex; site-directed mutagenesis (Arg125A); EMSA; transcriptional reporter assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and functional reporter assays\",\n      \"pmids\": [\"19098713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RelB has a bipartite arginine/lysine-rich NLS that mediates binding to importin α5 and α6 for nuclear import; nuclear import of p52/RelB heterodimers is mediated exclusively by the RelB NLS, not the p52 NLS.\",\n      \"method\": \"In vitro binding assays with importin α isoforms; nuclear translocation assays; NLS-mutant RelB constructs; viral infection and TNF stimulation models\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assays and NLS-mutant constructs, single lab\",\n      \"pmids\": [\"18462924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Daxx represses RelB target genes (dapk1, dapk3, c-flip, birc3/ciap2) by recruiting DNA methyltransferase 1 (Dnmt1) to their promoters in a RelB-dependent manner, resulting in DNA hypermethylation; methylation of target promoters is decreased in daxx-KO cells and restored by re-introduction of Daxx.\",\n      \"method\": \"ChIP; bisulfite sequencing/methylation analysis; daxx-KO and relB-KO cells; Daxx/Dnmt1 co-immunoprecipitation; reporter assays; stable transfection rescue\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, genetic KO with rescue, co-IP, and methylation quantification, multiple orthogonal methods\",\n      \"pmids\": [\"18413714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RelB is required for osteoclast differentiation downstream of NIK; deletion of p100 restores differentiation of NIK-deficient OC precursors; overexpression of RelB (but not p65) rescues NIK-deficient precursors; RelB-KO precursors fail to form OCs and this defect is rescued specifically by RelB re-expression; RelB-KO mice show diminished osteoclastogenic response to TNFα in vivo.\",\n      \"method\": \"NIK-KO and RelB-KO mice; p100-KO epistasis; retroviral overexpression of RelB vs p65; in vitro osteoclast differentiation assays; in vivo TNFα challenge; B16 melanoma bone tumor model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, rescue experiments, and in vivo validation\",\n      \"pmids\": [\"18322009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RelB NF-κB reciprocally inhibits estrogen receptor α (ERα) synthesis in breast cancer cells by inducing expression of the zinc finger repressor Blimp1 (PRDM1), which then represses ESR1 gene transcription; PRDM1 induction by RelB involves Bcl-2/Ras signaling.\",\n      \"method\": \"siRNA knockdown of RelB; reporter assays for ESR1/PRDM1 promoters; Western blot and RT-PCR in breast cancer cell lines; ChIP; migration assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA, ChIP, and reporter assays with functional migration readout, single lab\",\n      \"pmids\": [\"19433448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human requiem protein (REQ/DPF2) acts as an adaptor molecule linking the NF-κB p52 subunit to the Brm-type SWI/SNF chromatin remodeling complex; REQ and Brm form a larger complex with RelB/p52 upon lymphotoxin stimulation and are recruited to the BLC (CXCL13) promoter; REQ knockdown suppresses anchorage-independent growth of cell lines with constitutively activated noncanonical NF-κB.\",\n      \"method\": \"In vitro binding assays; co-immunoprecipitation; ChIP at BLC promoter; siRNA knockdown of REQ and Brm; reporter assays; soft-agar anchorage-independent growth assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and ChIP with functional knockdown, single lab\",\n      \"pmids\": [\"20460684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The paracaspase MALT1 cleaves RelB after Arg-85; RelB cleavage induces its proteasomal degradation and specifically enables DNA binding by RelA- or c-Rel-containing canonical NF-κB complexes; overexpression of uncleaved RelB inhibits canonical NF-κB target gene expression and impairs survival of DLBCL cell lines with constitutive MALT1 activity.\",\n      \"method\": \"In vitro MALT1 cleavage assay; mass spectrometry identification of cleavage site; proteasome inhibitor rescue; RelB overexpression in DLBCL lines; siRNA; reporter assays; EMSA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro cleavage assay identifying specific site (Arg-85), MS confirmation, multiple cell-based validations\",\n      \"pmids\": [\"21873235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"During dendritic cell activation, RelB functions primarily as a RelB–p50 dimer regulated by canonical IκBs (IκBα and IκBɛ), not as the expected RelB–p52 effector of the noncanonical pathway; IκB control of RelB minimizes spontaneous DC maturation but enables rapid pathogen-responsive maturation; computational modeling predicted that fibroblasts engineered to express DC-like IκB profiles show DC-like RelB control.\",\n      \"method\": \"Genetic mouse models (IκBα-KO, IκBɛ-KO, p52-KO); ChIP; Western blot; computational modeling of NF-κB signaling module; engineered fibroblast DC-like IκB reconstitution\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic KO models, ChIP, computational + experimental validation in engineered cells\",\n      \"pmids\": [\"23086447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LTβR signaling activates the NF-κB2–RelB pathway in adipocyte precursor mesenchymal cells, blocking adipogenesis (suppressing Pparγ and Cebpα expression) and redirecting differentiation toward lymph node stromal cells during embryonic lymph node development.\",\n      \"method\": \"LTβR-KO and NF-κB2/RelB pathway genetic models; in vivo organogenesis assay; transplantation of embryonic adipocyte precursors into newborn lymph nodes; RT-PCR for adipogenic markers\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic models and in vivo organogenesis, single lab\",\n      \"pmids\": [\"22940098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hypercapnia (elevated CO2) induces cleavage of RelB to a lower-molecular-weight form and promotes its nuclear translocation in mouse embryonic fibroblasts and human pulmonary epithelial cells (A549); this processing is sensitive to proteasomal inhibition (MG-132) but independent of GSK3β or MALT1 activity.\",\n      \"method\": \"Western blot for RelB cleavage product; nuclear fractionation; proteasome inhibitor (MG-132); GSK3β inhibitor; MALT1 deficiency; in vivo hypercapnia lung injury model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic dissection of cleavage mechanism with in vivo correlation, single lab\",\n      \"pmids\": [\"22396550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RelB directly targets the Runx2 promoter to inhibit its activation, thereby negatively regulating osteoblast differentiation and bone formation; RelB-KO mice develop increased trabecular bone mass with age and enhanced osteoblast differentiation associated with increased Runx2.\",\n      \"method\": \"RelB-KO mice; ChIP at Runx2 promoter; reporter assays; in vitro osteoblast differentiation; tibial bone defect transplantation model\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with KO phenotype and in vivo bone defect model, single lab\",\n      \"pmids\": [\"24115294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"An HDAC4–RelB–p52 complex maintains repressive chromatin around proapoptotic genes Bim and BMF in multiple myeloma; disruption of the RelB–HDAC4 interaction (by an HDAC4-mimetic polypeptide) blocks MM growth; RelB–p52 also represses BMF translation by regulating miR-221 expression; RelB is constitutively phosphorylated by ERK1 in MM, and phospho-RelB remains nuclear and is essential for Bim repression.\",\n      \"method\": \"Co-immunoprecipitation (HDAC4–RelB); ChIP at Bim/BMF promoters; HDAC4-mimetic polypeptide disruption; ERK1 kinase assay; siRNA for ERK1; reporter assays; in vivo xenograft growth assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — co-IP, ChIP, kinase assay identifying ERK1 as RelB kinase, peptide disruption with functional growth readout, multiple orthogonal methods\",\n      \"pmids\": [\"26455434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RelB/p50 complexes (not p65) directly bind to the YKL-40 promoter in astrocytes and are required for cytokine-driven (IL-1 + oncostatin M) YKL-40 expression; IL-1 promotes RelB/p50 complex formation further enhanced by oncostatin M; dominant-negative IκBα but not p65 depletion inhibits YKL-40.\",\n      \"method\": \"ChIP at YKL-40 promoter; reporter assays with NF-κB site mutagenesis; p65 siRNA vs RelB/p50 manipulation; co-immunoprecipitation of RelB/p50; primary human and mouse astrocytes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, co-IP, promoter mutagenesis, and siRNA in primary cells, single lab\",\n      \"pmids\": [\"25681350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PAK4 phosphorylates RelB at Ser151, which is critical for RelB–DNA interaction and transcriptional activity; PAK4–RelB–C/EBPβ axis controls senescence-like growth arrest in breast cancer cells; loss of PAK4 increases RELB-driven C/EBPβ expression and triggers senescence.\",\n      \"method\": \"PAK4 kinase assay on RelB; phospho-mutant RelB (S151A); ChIP; siRNA/shRNA knockdown; mammary tumorigenesis in MMTV-PAK4 and MMTV-PyMT mouse models; senescence assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — kinase assay identifying PAK4 as RelB Ser151 kinase, mutagenesis with DNA binding/transcription readout, in vivo mouse models\",\n      \"pmids\": [\"31399573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Relb acts downstream of SSEA-1+ mTEC stem cells and is necessary for effective production of RANK+ mTEC progenitors; SSEA-1+ mTEC stem cells are present in Relb-KO mice (demonstrating mTEC lineage specification is Relb-independent), but downstream RANK+ progenitor emergence requires Relb.\",\n      \"method\": \"RANK Venus reporter mice; Relb-KO and nude (Foxn1-KO) mice; flow cytometry for RANK/SSEA-1 co-expression; histological analysis of thymus development\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with stage-specific developmental readout using reporter mice, single lab\",\n      \"pmids\": [\"26806881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DeficiencyofRelB in nonhematopoietic stromal cells (extrinsic) rather than cDC intrinsic mechanisms accounts for myeloid expansion and most cDC development defects in Relb-KO mice; cell-intrinsic RelB is required specifically for the Notch2- and LTβR-dependent splenic CD4+ cDC2 subset.\",\n      \"method\": \"Radiation chimeras (wild-type vs Relb-KO bone marrow in Relb-KO vs WT hosts); flow cytometry for DC subsets; conditional analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic series of reciprocal radiation chimeras cleanly dissecting cell-intrinsic vs extrinsic requirements\",\n      \"pmids\": [\"28348230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RELB nuclear translocation in cholangiocytes is required for the ductular reaction and biliary fibrosis downstream of CYLD loss; LTβ–RELB axis promotes cholangiocyte proliferation; genetic co-deletion of Relb with Cyld in liver parenchymal cells abolishes ductular reaction, oval cell activation, and biliary fibrosis.\",\n      \"method\": \"Genetic double-KO mice (Cyld/RelbΔLPC); DDC diet model; siRNA knockdown of RELB in human cholangiocytes + LTβR agonist; ChIP; IHC; in situ hybridization\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-KO epistasis with in vitro siRNA rescue, multiple disease models\",\n      \"pmids\": [\"30445013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GSK3β modulates RelB degradation via BCL10 phosphorylation; GSK3β inhibition or knockdown reduces MALT1-dependent proteolysis of RelB (and other MALT1 substrates) by diminishing CBM complex formation; this links GSK3β to the control of MALT1-mediated RelB cleavage in T cell activation.\",\n      \"method\": \"GSK3β pharmacologic inhibitors (SB216763, SB415286); siRNA knockdown; Western blot for RelB proteolysis; NF-κB reporter assay; co-immunoprecipitation of CBM complex\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic inhibition with co-IP and functional readouts, single lab\",\n      \"pmids\": [\"29358699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RelB transcriptionally upregulates PD-L1 (CD274) by binding to a proximal NF-κB enhancer element in the CD274 promoter; RelB silencing in prostate cancer cells reduces PD-L1 expression and enhances susceptibility to CD4+/CD8+ T cell killing in vitro and in vivo.\",\n      \"method\": \"ChIP at CD274 promoter; reporter assays with promoter mutagenesis; siRNA/shRNA knockdown of RelB; T cell co-culture cytotoxicity assays; in vivo xenograft and metastasis models\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, promoter mutagenesis, and functional T cell killing assay with in vivo validation, single lab\",\n      \"pmids\": [\"35177112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RelB confers tamoxifen resistance in breast cancer by transcriptionally upregulating GPX4, thereby inhibiting ferroptosis; elevated RelB–GPX4 axis in TAM-resistant cells alleviates TAM-induced ROS accumulation and ferroptotic cell death; suppression of RelB or GPX4 resensitizes resistant cells to tamoxifen in vitro and in vivo.\",\n      \"method\": \"ChIP at GPX4 promoter; reporter assays; siRNA/shRNA knockdown of RelB and GPX4; ferroptosis assays (lipid ROS, cell death markers); in vivo xenograft models\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, siRNA, and in vivo xenograft, single lab\",\n      \"pmids\": [\"37944384\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RelB is an NF-κB family transcription factor that functions primarily as a heterodimer (with p50 or p52) to activate κB-dependent gene transcription via a C-terminal transactivation domain; it is held inactive in the cytoplasm by p100, which acts as a dedicated IκB, and is released by NIK/IKKα-dependent p100 processing in the alternative (noncanonical) NF-κB pathway; RelB can also form transcriptionally inactive complexes with RelA to dampen canonical NF-κB responses; it undergoes signal-specific phosphorylation (at Thr84/Ser552 by T cell signals, Ser151 by PAK4, and Ser368 for dimerization) and proteasomal degradation, as well as cleavage by MALT1 paracaspase after Arg-85; RelB is stabilized by interaction with p100/p52 through unique multi-domain contacts; in dendritic cells it drives maturation and antigen-presenting function, in osteoclast precursors it is required downstream of NIK for differentiation, in stromal cells it controls lymphoid organ microarchitecture and homing chemokine expression, and in cancer cells it drives resistance to therapy by upregulating MnSOD, GPX4, and PD-L1, among other targets.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RelB is an NF-κB family transcription factor that controls immune organ development, dendritic cell and osteoclast differentiation, and stress/cancer gene programs through κB-dependent transcription [#0, #2, #26]. It carries a C-terminal transactivation domain and cannot bind κB DNA as a monomer; instead it forms transactivating heterodimers with p50 and p52, with crystallographic work showing p52:RelB engages a broader spectrum of κB sites (including AT-rich elements) than p50:RelA via RelB Arg125 [#0, #1, #23]. RelB is held inactive in the cytosol through direct association with the NF-κB2 precursor p100, which acts as a dedicated IκB-like inhibitor via a region encompassing a nuclear export signal; NIK/IKKα-dependent p100 processing in the noncanonical (LTβR-driven) pathway releases p52:RelB for nuclear import through RelB's own bipartite NLS and importin α5/α6 [#5, #10, #12, #24]. RelB also forms transcriptionally inactive complexes with RelA/p65 that fail to bind κB DNA and dampen canonical NF-κB responses, a mechanism exploited during endotoxin tolerance [#11, #19]. Its activity is shaped by signal-specific post-translational control: phosphorylation at Thr84/Ser552 triggers proteasomal degradation after T-cell activation, MALT1 cleaves RelB after Arg-85 to license canonical NF-κB DNA binding, PAK4 phosphorylates Ser151 and ERK1 phosphorylation sustains nuclear RelB activity, and Ser368 governs dimerization [#8, #9, #29, #34, #36]. Developmentally, RelB acts largely in radiation-resistant stromal cells to build splenic germinal centers, follicular dendritic cell networks, marginal zones, thymic medulla and lymph-node stroma, and to drive homing chemokine expression, while acting downstream of NIK in osteoclast precursors and as a direct Runx2 repressor in osteoblasts [#2, #7, #26, #31, #33, #38]. RelB pairs with the aryl hydrocarbon receptor to drive non-canonical target genes including IL-8, BAFF and BLC, and recruits chromatin regulators such as Daxx/Dnmt1 and HDAC4 to repress target loci [#20, #22, #25, #34]. In cancer it functions as a survival and resistance factor, transcriptionally upregulating MnSOD, PD-L1 (CD274), GPX4, and Bcl-2 to confer radioresistance, immune evasion, ferroptosis resistance, and an invasive phenotype [#18, #21, #41, #42].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established that RelB is a transactivator rather than an inhibitor, defining its core biochemical mode as a heterodimer-dependent activator of κB transcription.\",\n      \"evidence\": \"GAL4-RelB fusion activation assays, EMSA, and reporter assays showing RelB requires p50 heterodimerization to bind κB sites\",\n      \"pmids\": [\"1732739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which physiological signals control RelB dimer formation\", \"Did not address p52 partnering or in vivo relevance\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Confirmed that human RelB behaves like its murine counterpart, forming transactivating heterodimers with p50 and p52, extending the activator model across species.\",\n      \"evidence\": \"Transfection reporter assays and EMSA of human RelB (I-Rel) heterodimeric complexes\",\n      \"pmids\": [\"8183565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, did not address regulation or knockout phenotype\", \"p52 vs p50 functional differences not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated the non-redundant in vivo role of RelB in thymic medulla and dendritic cell development, linking the transcription factor to immune homeostasis.\",\n      \"evidence\": \"relB germline knockout mice with EMSA, histology, and contact sensitivity assays; replicated by an independent lab\",\n      \"pmids\": [\"7834753\", \"7845467\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish cell-intrinsic from cell-extrinsic requirements\", \"Molecular target genes underlying phenotypes unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed the inflammatory and myeloid phenotypes of RelB-deficient mice are T-cell dependent, reframing the defect as dysregulated immune cross-talk rather than a purely cell-autonomous lesion.\",\n      \"evidence\": \"Genetic epistasis with RelB-KO × RAG-1-KO and RelB-KO × Nur77-Tg double-mutant mice\",\n      \"pmids\": [\"8892630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the stromal vs hematopoietic source of the requirement\", \"Mechanism of aberrant T-cell activation unresolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified RelB as a negative regulator of chemokine expression in fibroblasts, revealing a repressive arm of its activity distinct from transactivation.\",\n      \"evidence\": \"LPS stimulation of RelB-KO fibroblasts with EMSA, chemokine quantification, and RelB cDNA rescue plus in vivo recruitment assay\",\n      \"pmids\": [\"9250151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of chemokine repression (dimer composition) not defined\", \"Did not identify direct promoter targets\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined p100 as the dedicated cytoplasmic inhibitor of RelB and tied its release to NIK/IKKα-driven p100 processing, establishing RelB as the effector of the noncanonical pathway.\",\n      \"evidence\": \"Co-IP, nuclear fractionation, p100 deletion mapping, and NIK overexpression\",\n      \"pmids\": [\"11687592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how RelB selects p50 vs p52 partners after release\", \"Kinetics of processing in physiological signaling not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed RelB is a transcriptional target of RelA, explaining the delayed kinetics of RelB activity as transcriptional induction rather than IκB-mediated retention.\",\n      \"evidence\": \"RELB promoter cloning, EMSA at κB sites, and TNF/LPS time-course with nuclear fractionation\",\n      \"pmids\": [\"11753650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address additional promoter inputs (AP-1, hormone receptors)\", \"Cross-talk with p100-mediated retention not integrated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapped Ser368 as essential for RelB dimerization and showed RelB feedback-inhibits its own p100 processing, revealing a self-limiting regulatory loop.\",\n      \"evidence\": \"Site-directed mutagenesis (S368A/D), co-IP, and pulse-chase of p100 stability in plasmacytoma cells\",\n      \"pmids\": [\"12874295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Physiological consequence of the feedback loop in vivo untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Established signal-specific proteasomal turnover of RelB driven by Thr84/Ser552 phosphorylation upon T-cell activation, introducing degradative control of RelB stability.\",\n      \"evidence\": \"T84A/S552A phosphosite mutagenesis, proteasome inhibition, and TCR/TPA stimulation of T cells\",\n      \"pmids\": [\"11781828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase(s) for Thr84/Ser552 not identified\", \"Relationship to the later-defined N-terminal MALT1 cleavage unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Distinguished two p100-based mechanisms for signal-specific RelB control — IKKα-dependent processing under LTβR vs TNF-induced p100–RelB/p50 sequestration — clarifying how distinct stimuli route RelB.\",\n      \"evidence\": \"IKK and RelA knockout MEFs with EMSA and Co-IP under LTβR vs TNF stimulation; complementary NIK/NF-κB2 knockout in vivo work\",\n      \"pmids\": [\"12709443\", \"12505990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define molecular basis of TNF-induced sequestration\", \"Cell-type specificity of the two mechanisms unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified inhibitory RelA·RelB heterodimers that cannot bind κB DNA, providing a mechanism by which RelB restrains canonical NF-κB output.\",\n      \"evidence\": \"Reporter assays, EMSA with in vitro translated proteins, Co-IP, and RelB overexpression in MEFs\",\n      \"pmids\": [\"12657634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance and stoichiometry of the dimer not established\", \"Structural basis of DNA-binding incompetence not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed RelB requires stromal-cell expression to build germinal centers, FDC networks, and marginal zones, separating cell-extrinsic architectural roles from hematopoietic functions.\",\n      \"evidence\": \"Reciprocal bone marrow chimeras, immunofluorescence, and chemokine RT-PCR in RelB-KO spleen\",\n      \"pmids\": [\"11489970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct stromal target genes beyond BLC not mapped\", \"Mechanism of FDC patterning unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated RelB acts in stromal cells downstream of NIK for dendritic cell-mediated NKT cell development, providing in vivo genetic evidence for a NIK–RelB axis.\",\n      \"evidence\": \"RelB-KO and aly/aly NIK-mutant mice, bone marrow chimeras, compound heterozygous epistasis, and in vitro NIK kinase assay\",\n      \"pmids\": [\"12810685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NIK phosphorylation target in the pathway not pinpointed\", \"Stromal RelB target genes for NKT development unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed RelB transcription is directly repressed by vitamin D via VDR·RXRα binding to relB promoter VDREs, identifying a hormonal brake on RelB independent of NF-κB signaling.\",\n      \"evidence\": \"VDRE identification, gel shift, reporter assays with VDRE mutagenesis, and VDR-KO mouse comparison\",\n      \"pmids\": [\"14507914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not yet define the chromatin co-repressor machinery\", \"Physiological context of vitamin D repression unaddressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the chromatin mechanism of vitamin D repression of RelB as VDR-recruited HDAC3, connecting hormonal signaling to histone deacetylation at the relB promoter.\",\n      \"evidence\": \"ChIP, HDAC inhibitor assays, HDAC3 overexpression/knockdown, and in vivo VDR-KO mice\",\n      \"pmids\": [\"16239345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address LPS-induced reversal mechanism in detail\", \"Generalizability beyond dendritic cells unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked IKKα-driven p52/RelB transcription to cell-cycle control via Skp2/p27Kip1, extending RelB function into proliferation in cancer cells.\",\n      \"evidence\": \"IKKα siRNA, ChIP at the skp2 promoter, reporter assays, and cell cycle analysis in pancreatic cancer cells\",\n      \"pmids\": [\"16902410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct RelB occupancy vs IKKα-mediated indirect effects not fully separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified RelB as a driver of antioxidant defense and radioresistance through MnSOD upregulation, establishing a cytoprotective role in cancer therapy resistance.\",\n      \"evidence\": \"Dominant-negative p100, RelB siRNA, MnSOD Western blot, and clonogenic radiation survival assay in prostate cancer cells\",\n      \"pmids\": [\"16261162\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RelB binding at the MnSOD promoter not shown here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed RelB induction during endotoxin tolerance represses proinflammatory genes via inactive p65/RelB dimers, providing a mechanistic basis for tolerance.\",\n      \"evidence\": \"THP-1 tolerance model with RelB siRNA rescue, Co-IP of p65/RelB, EMSA, and reporter assays\",\n      \"pmids\": [\"16951372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Genome-wide scope of RelB-mediated repression undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovered the RelB–AhR complex binding novel response elements to drive IL-8 and immune genes, revealing a non-canonical, ARNT-independent transcriptional partnership.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP at IL-8 promoter, reporter assays, PKA modulation, and EMSA; corroborated by AhR/RelB occupancy on BAFF, BLC, CCL1, IRF3 promoters\",\n      \"pmids\": [\"17823304\", \"17900530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and DNA-binding subunit of the RelB/AhR complex unresolved\", \"Physiological xenobiotic contexts incompletely defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined constitutive RelB synthesis in ERα-negative breast cancer via NF-κB/AP-1 promoter synergy and its pro-invasive output through Bcl-2, embedding RelB in tumor aggressiveness.\",\n      \"evidence\": \"EMSA, ChIP, promoter mutagenesis reporters, siRNA, invasion assays, and breast tumor IHC correlation\",\n      \"pmids\": [\"17369819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the ERα-RelB reciprocal loop mechanism (addressed later)\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided the structural basis for RelB's distinct DNA-site preference, showing p52:RelB accommodates AT-rich κB sites via Arg125, explaining target-gene selectivity.\",\n      \"evidence\": \"X-ray crystallography of the p52:RelB:κB DNA complex with Arg125A mutagenesis, EMSA, and reporter assays\",\n      \"pmids\": [\"19098713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of RelB with other partners (RelA, p50) not solved\", \"Genome-wide consequences of broadened site preference untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined RelB's intrinsic bipartite NLS and importin α5/α6 usage, showing RelB nuclear import drives p52/RelB translocation independent of the p52 NLS.\",\n      \"evidence\": \"In vitro importin binding assays and NLS-mutant RelB nuclear translocation assays\",\n      \"pmids\": [\"18462924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Regulation of NLS exposure by p100 not mechanistically linked\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed RelB stability depends on multi-domain contacts with p100/p105/p52/p50, establishing that the same precursor proteins both inhibit and protect RelB.\",\n      \"evidence\": \"Co-IP, domain mapping of p100 and RelB, and Western blot in p100-KO and p100/p105 double-KO cells\",\n      \"pmids\": [\"18321863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each domain to half-life not defined\", \"Link between stabilization and degradative phosphorylation pathways unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Daxx/Dnmt1-mediated DNA hypermethylation as a RelB-dependent mechanism for epigenetic silencing of RelB target genes, expanding RelB into chromatin-level gene control.\",\n      \"evidence\": \"ChIP, bisulfite methylation analysis, daxx-KO/relB-KO cells with rescue, and Daxx/Dnmt1 Co-IP\",\n      \"pmids\": [\"18413714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling Daxx recruitment to RelB sites unknown\", \"Generality across RelB target sets undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established RelB as the essential NF-κB effector downstream of NIK for osteoclast differentiation, with p100 deletion bypassing the NIK requirement.\",\n      \"evidence\": \"NIK-KO/RelB-KO mice, p100-KO epistasis, retroviral RelB vs p65 rescue, osteoclast differentiation assays, and in vivo TNFα challenge\",\n      \"pmids\": [\"18322009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RelB osteoclastogenic target genes not mapped here\", \"Dimer partner in osteoclast precursors not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the reciprocal RelB–ERα antagonism via RelB-induced Blimp1 repression of ESR1, mechanistically connecting RelB activation to estrogen-independent breast cancer.\",\n      \"evidence\": \"RelB siRNA, ESR1/PRDM1 reporter assays, ChIP, and migration assays in breast cancer lines\",\n      \"pmids\": [\"19433448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect RelB control of PRDM1 not fully resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified REQ/DPF2 as an adaptor linking p52 to the Brm SWI/SNF complex at the BLC promoter, showing RelB/p52 recruits chromatin-remodeling machinery for target activation.\",\n      \"evidence\": \"In vitro binding, Co-IP, ChIP at the BLC promoter, REQ/Brm knockdown, and soft-agar growth assay\",\n      \"pmids\": [\"20460684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generality of REQ-dependent remodeling across RelB targets untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovered MALT1 cleavage of RelB after Arg-85 as a switch that licenses canonical NF-κB DNA binding, mechanistically integrating RelB into lymphoma signaling.\",\n      \"evidence\": \"In vitro MALT1 cleavage assay with MS site identification, proteasome rescue, and RelB overexpression in DLBCL lines with reporter/EMSA\",\n      \"pmids\": [\"21873235\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream regulators of MALT1-RelB cleavage only partly defined\", \"In vivo physiological scope beyond DLBCL unaddressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed that during DC activation RelB operates as a canonical-IκB-controlled RelB–p50 dimer rather than the expected p52 effector, refining the pathway logic of RelB control.\",\n      \"evidence\": \"IκBα-KO, IκBε-KO, p52-KO mice, ChIP, Western blot, and computational modeling validated in engineered fibroblasts\",\n      \"pmids\": [\"23086447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell types where RelB-p52 dominates vs RelB-p50 not fully delineated\", \"Quantitative dimer partitioning in vivo unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed the NF-κB2–RelB pathway blocks adipogenesis and redirects mesenchymal precursors toward lymph-node stroma, extending RelB into stromal cell-fate decisions.\",\n      \"evidence\": \"LTβR-KO and NF-κB2/RelB genetic models with in vivo organogenesis and precursor transplantation assays\",\n      \"pmids\": [\"22940098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct RelB target genes controlling adipogenic suppression not mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified hypercapnia-induced proteasome-dependent RelB cleavage independent of GSK3β/MALT1, indicating a distinct stimulus-specific processing route.\",\n      \"evidence\": \"Western blot for cleavage product, nuclear fractionation, MG-132, GSK3β inhibitor, MALT1 deficiency, and in vivo lung injury model\",\n      \"pmids\": [\"22396550\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease responsible for hypercapnia-induced cleavage unidentified\", \"Functional transcriptional consequences not fully defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established RelB as a direct repressor of Runx2 limiting osteoblast differentiation, complementing its osteoclast role to define bidirectional control of bone.\",\n      \"evidence\": \"RelB-KO mice, ChIP at the Runx2 promoter, reporter assays, osteoblast differentiation, and bone defect transplantation\",\n      \"pmids\": [\"24115294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Dimer partner mediating Runx2 repression not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined an HDAC4–RelB–p52 repressive complex sustaining myeloma survival via Bim/BMF silencing and identified ERK1 as a RelB kinase maintaining nuclear activity, adding a kinase-driven survival mechanism.\",\n      \"evidence\": \"HDAC4–RelB Co-IP, ChIP at Bim/BMF, HDAC4-mimetic peptide disruption, ERK1 kinase assay, and xenograft growth assay\",\n      \"pmids\": [\"26455434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ERK1 phosphosite on RelB not specified\", \"Generality of HDAC4-RelB axis beyond myeloma unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed RelB/p50 (not p65) directly drives cytokine-induced YKL-40 expression in astrocytes, demonstrating RelB-specific transcriptional control in CNS inflammation.\",\n      \"evidence\": \"ChIP at the YKL-40 promoter, NF-κB-site mutagenesis reporters, p65 vs RelB/p50 manipulation, and Co-IP in primary astrocytes\",\n      \"pmids\": [\"25681350\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Upstream signaling controlling RelB/p50 formation only partly defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified PAK4-mediated Ser151 phosphorylation as critical for RelB DNA binding, linking a kinase to RelB transcriptional activity and senescence control in breast cancer.\",\n      \"evidence\": \"PAK4 kinase assay on RelB, S151A phospho-mutant, ChIP, knockdowns, and MMTV-PAK4/PyMT mouse models\",\n      \"pmids\": [\"31399573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between Ser151, Ser368, and degradative phosphosites unresolved\", \"Tissue scope of PAK4-RelB axis beyond breast not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed Relb acts downstream of mTEC stem cells to generate RANK+ mTEC progenitors, refining its developmental position in thymic epithelial differentiation.\",\n      \"evidence\": \"RANK Venus reporter and Relb-KO/nude mice with flow cytometry and thymic histology\",\n      \"pmids\": [\"26806881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct RelB target genes in mTEC progenitor emergence unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Dissected cell-intrinsic vs extrinsic RelB requirements in cDC development, attributing most defects to stromal RelB while assigning intrinsic RelB to a specific cDC2 subset.\",\n      \"evidence\": \"Systematic reciprocal radiation chimeras with DC-subset flow cytometry\",\n      \"pmids\": [\"28348230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stromal RelB target genes governing DC homeostasis not mapped\", \"Molecular basis of the Notch2/LTβR-dependent cDC2 requirement undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established the LTβ–RELB axis as the driver of cholangiocyte ductular reaction and biliary fibrosis downstream of CYLD loss, extending RelB into liver disease pathology.\",\n      \"evidence\": \"Cyld/Relb double-KO mice, DDC diet model, RELB siRNA in human cholangiocytes with LTβR agonist, and ChIP\",\n      \"pmids\": [\"30445013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RelB fibrogenic target genes not detailed\", \"Translational relevance to human cholangiopathies untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked GSK3β to RelB turnover through BCL10 phosphorylation and CBM complex assembly, identifying an upstream modulator of MALT1-mediated RelB cleavage.\",\n      \"evidence\": \"GSK3β inhibitors and siRNA, Western blot for RelB proteolysis, NF-κB reporters, and CBM complex Co-IP\",\n      \"pmids\": [\"29358699\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct GSK3β substrate phosphosite on BCL10 vs other CBM components not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified RelB as a direct transcriptional activator of PD-L1, establishing a mechanism for RelB-driven tumor immune evasion.\",\n      \"evidence\": \"ChIP at CD274 promoter, promoter-mutagenesis reporters, RelB knockdown, T-cell co-culture cytotoxicity, and xenograft/metastasis models\",\n      \"pmids\": [\"35177112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Dimer partner driving CD274 transcription not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed RelB confers tamoxifen resistance by upregulating GPX4 and suppressing ferroptosis, linking RelB to redox-dependent therapy resistance.\",\n      \"evidence\": \"ChIP at GPX4 promoter, reporter assays, RelB/GPX4 knockdown, ferroptosis assays, and xenograft models\",\n      \"pmids\": [\"37944384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Upstream signals activating RelB in resistant cells not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple phosphorylation marks (Thr84/Ser552, Ser151, Ser368, ERK1 sites), MALT1 cleavage, and p100-mediated stabilization are integrated into a single regulatory logic that selects RelB dimer partner, stability, and target-gene program in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTMs to dimer choice and target selection\", \"Genome-wide RelB cistrome across cell types and stimuli not defined\", \"Structural basis of RelA·RelB inactive dimers unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 23, 21, 41, 42]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 23, 35]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 24, 30, 39]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 11]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [30, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 23, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 7, 12, 38]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [26, 31, 33, 37]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [25, 28, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [18, 21, 41, 42, 39]}\n    ],\n    \"complexes\": [\n      \"RelB:p50 NF-κB heterodimer\",\n      \"RelB:p52 NF-κB heterodimer\",\n      \"RelB:RelA (inactive) heterodimer\",\n      \"HDAC4–RelB–p52 repressor complex\"\n    ],\n    \"partners\": [\n      \"NFKB2/p100/p52\",\n      \"NFKB1/p50\",\n      \"RELA\",\n      \"AHR\",\n      \"HDAC4\",\n      \"DAXX\",\n      \"MALT1\",\n      \"DPF2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}